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Abstract  
 
Colloidal inorganic nanoparticles (NPs) have been attracting considerable interest in 
biomedicine, from drug and gene delivery to imaging, sensing and diagnostics. It is 
essential to modify the surface of nanoparticles to have enhanced biocompatibility and 
functionality for the in vitro and in vivo applications, especially in delivering locally and 
recognizing biomolecules. Herein, the goal of this research work is to develop advanced 
NPs with well-tailored surface functionalities and/or bio-functionality for the applications 
in cell tracking and analytes detection. 
In the first project, quantum dots incorporating with gelatin nanoparticles (QDs-GNPs) 
have been developed for bioimaging applications. Two different approaches have been 
developed, i.e. directly encapsulating QDs with gelatin polymer (QDs-GNP1) and layer-
by-layer (LBL) adsorption of QDs approach (QDs-GNP2), respectively. The special 
hybrid structures of two QDs-GNPs nanosystems were investigated by transmittance 
electron microscopy, scanning electron microscopy, X-ray energy dispersion, Fourier 
Transform Infrared spectroscopy, fluorometer, and confocal fluorescent microscopy. Both 
nanosystems exhibit high intensive luminescence and good biocompatibility. Compared 
to free QDs, QDs-GNP2 shows improved quantum yield and longer lifetime, due to 
multiple layers of polyelectrolytes protection. Furthermore, QDs-GNP2 demonstrates the 
proton-resistant properties in term of PL intensity and lifetime. The bright and stable 
photoluminescence (PL) allows the QD-GNP2 for labeling living 3T3 cells in vitro, 
which may indicate the QDs-GNP2 are able to be a suitable candidate for bio-imaging 
application. 
In the second project, fluorescent magnetic nanoparticles (FMNPs) were bioconjugated 
with gentamicin (Gm) for rapid capture, detection and decontamination of bacteria. The 
Gm-FMNPs consist of a fluorescent silica shell and an iron oxide magnetic core. Initially, 
we prepared the core-shell NPs through a one-pot reaction. The antibacterial efficiency is 
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found 20 % higher than that of the free antibiotic. We further improved NPs stability and 
capture efficiency by a two-step thermal decomposition method to produce the 
fluorescent magnetic core-shell nanoparticles. It is noted that one mg of gentamicin 
conjugated FMNPs are able to capture both gram-negative bacteria Escherichia coli and 
gram-positive bacteria Staphylococcus aureus as low as 1x104 colony-forming unit/mL 
(cfu/mL) in less than one minute. It is expected that the Gm-FMNPs could be a promising 
multifunctional platform for disease control in clinic and wastewater treatment. 
In addition, a nanosensor for detecting human thrombin has been designed and 
developed. A recombinant luciferase was covalently conjugated to gold nanoparticles (Au 
NPs) through 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) mediated reaction. 
The conjugation enables Au NPs to quench the bioluminescence produced by luciferase. 
Recovery of bioluminescence has been studied as a function of the concentration of 
thrombin. The results indicate that the designed nanosensor can efficiently detect a 
protease thrombin in both buffer and human urine spiked buffer. A linear assay response 
is found between 300 ng/mL to 300 µg/mL, with limit of detection (LOD) of 3 ng/mL in 
both buffer and human urine spiked samples. The assay time can be less than 15 min. The 
nanosensor can thus be a promising tool for clinical diagnostic of thrombin related 
diseases. 
In summary, different strategies have been explored to engineer the surface of hybrid NPs 
with good water stability, biocompatibility and enhanced chemical and physical 
properties. The thesis addresses that engineered hybrid NPs in biomedicine and how the 
biofunctionalized NPs can find applications in imaging and diagnostics indistinctly. 
 
Keywords:  Fluorescent, magnetic, nanoparticles, gold nanoparticles, quantum dots, 
surface functionalization, bioconjugation, biosensing, bioimaging. 
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CHAPTER 1 
GENERAL INTRODUCTION AND MOTIVATION  
 
 
2 
 
1.1 Overview of nanoparticles in biomedical applications 
The term “nanotechnology” is defined as the creation and utilization of materials, devices 
and systems through the control of matter at the length scale of 1 to 100 nanometer (nm), 
i.e. at atomic, molecular or supermacromolecular level.1 Yet, materials or structures with 
at least one dimension below 100 nm also enter into this definition. Materials built at this 
size scale (i.e. nanomaterials) often exhibit distinctive physical and chemical properties 
due to quantum mechanical effects and/or large surface-to-volume ratio.  
Since last decades, a variety of nanomaterials has been developed for both research and 
industrial applications. For example, zinc oxide nanocrystals have been fabricated and 
incorporated to sunscreens for blocking ultraviolet light; and silver nanoparticles have 
been coated or embedded in bandages to kill microbes and prevent post-surgery infection. 
Possibilities of application of nanomaterials are numerous, from producing energy saving 
battery for vehicle, to manufacturing materials with anti-corrosion and scathing surface; 
from fabricating chemical and biological sensors for health care, to environmental safety 
solar-energy panels. 
In recent, nanomaterials, in particular nanoparticles (NPs), offer immense potential for 
various biomedical applications from drug and gene delivery to imaging, sensing and 
diagnostics (Table 1.1), depending upon the nature of the materials and their chemical 
and physical properties. Of all biomedical applications, the development of nanoparticles 
based imaging agents for cancer therapy and biosensor for diagnostics stand out as the 
most prioritised areas of research.  
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Table 1.1 Typical inorganic nanoparticles and their general applications in biomedicine 
 
  
Category  Examples Intrinsic properties Biomedical applications 
 
 
Metallic NPs 
  
 Gold or 
Silver NPs 
 
Surface plasmon  
resonance (SPR), 
Surface reactivity, 
catalysis. 
 
 Chemical/biochemical sensing, 
disease diagnostics; Optical 
imaging, Raman probe; 
photothermal cancer therapy; 
 drug delivery; antimicrobial 
agents. 
 
Semiconduct 
NPs, or/ 
Quantum dots 
  
 CdSe, CdS, 
CdTe 
 
Fluorescence,  
Luminescence 
 High-resolution and sensitive 
cellular imaging; long-term cell 
trafficking; diagnostics and 
sensing based on energy transfer 
techniques. 
 
 
Magnetic NPs 
  
 Fe3O4, Co, 
FePt NPs 
Superparamagnetic, 
Large magnetic 
moments in a 
magnetic field 
 Magnetic separation for 
diagnosis and monitoring; target  
delivery of drugs & genes; MRI 
contrast agents; Thermotherapy. 
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1.1.1 Nanoparticles as imaging agents and biosensing transducer 
Molecular imaging and image-guided therapy is now emerging as a most promising basic 
tool for monitoring disease. A variety of imaging modalities such as optical imaging, 
magnetic resonance imaging (MRI), X-ray and ultrasound has been established for 
diagnose disease and cancer therapy. Yet, these techniques are generally not sensitive 
enough to detect tissue changes at molecular level that are usually the first signs of 
evolution of healthy body to diseased ones. Further improvement of imaging involves the 
design of novel contrast agents. The discovery and understanding of nanomaterials with 
unique size dependent physical and chemical features has drawn the attention of research 
in using nanoparticles as new contrast agents.  
The current types of NPs widely used as imaging agents are luminescent nanoprobes for 
optical imaging and magnetic nanoparticles for MRI. For example, the plasmon 
absorption and scattering properties make the use of gold nanoparticles in targeting and 
imaging of cells and cancer makers.2 Quantum dots (QDs) have been demonstrated to be 
excellent agents for optical imaging, because of their bright and stable 
photoluminescence. In particular, the tunable emission spectrum allows QDs emission at 
near-infrared light (700 nm -900 nm) which could effectively penetrate in deep tissue. 
Superparamagnetic properties of magnetic NPs provides contrast enhancement by 
facilitating MRI signal strengths for non-invasive imaging.3, 4 
Likewise, research in development of NPs based biosensors has showed highly 
fascinating and promising results in the early and accurate diagnosis of clinical 
conditions. For example, high surface to volume ratio of the nanomaterials enables the 
detection of biomolecules under extremely low concentration by using optical,5 electrical 
or electrochemical signal.6 Size-dependent physical and chemical properties make the use 
of NPs for high throughput labelling and detection of bioanalytes.7, 8 Furthermore, 
superparamagnetic NPs based systems that can be automated and miniaturized, which 
provide enormous advantages over others for their potentials use in field situations.9, 10 
Due to these great advantages, a number of nanosensors have now been developed in 
detection of proteins, nucleic acid, bioactive molecules, bacterial and viral agents.11, 12  
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A sensor generally consists of two components: a recognition element for target 
recognizing and a transducer to convert the biological events into measurable signal 
(typically optical signal). Bio-labelled NPs usually have been demonstrated to be 
excellent transducers. In this case, NPs with unique optical property can be directly 
labelled with a biological recognition element such as nucleic acid probe, antibody, 
enzyme, aptamer or small bioactive ligands for detection.13 The concentrations of the 
analytes are thus linked directly to the changes of optical signal.  
1.1.2 Fluorescence resonance energy transfer as readout  
Apart from providing signals for directly labelling in sensing and imaging applications, 
NPs can also provide fluorescent signals in the form of Förster/fluorescence resonance 
energy transfer (FRET), which is a process that nonradiative energy transfer occurs from 
an excited fluorophore (donor) to a proximal ground state fluorophore (acceptor). This 
process results in reduction of donor fluorescence intensity and increasing of acceptor 
emission intensity (Figure 1.1).14, 15 The efficiency of energy transfer is strongly 
dependent on the distance between the donor and acceptor. By measuring the efficiency 
of energy transfer (e.g. through the changes of fluorescent signal from either donor and/or 
acceptor), one can determine the distance between two fluorophore-partners. Based on 
this, FRET has shown as a powerful tool for probing biological interations, sensing 
analytes and imaging applications. 
The pair of donor and acceptor in conventional FRET system can be organic dyes pair 
(Cy3-Cy5), fluorescent proteins pair (e.g. cyan fluorescent protein and red fluorescen 
protein pair), or dye-fluorescent proteins pair. Fluorescent NPs, such as QDs can also be 
used in FRET system. For example, by taking the advantage of broad absorption spectra 
and tunable emission profile, QD is particularly suitable as a donor in the FRET 
system.16-18 Numerous investigators have utilized the QD-based FRET system for various 
applications, such as detection of pathogenic DNA and DNA point mutation,19, 20 
immunoassay,21, 22 tracking and quantifying enzyme activity,23-26 protein conformation 
changes,27, 28 sensing pH 29 and ion changes,30 and interaction between of biomolecules.28 
In some cases, the system was also used for multiplex detection of analytes.31  
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QDs can also be energy acceptor, particularly while incorporated into bioluminescence 
resonance energy transfer (BRET) 32 and chemiluminescence resonance energy transfer 
(CRET),33 whereby non-radiative energy transferring from substrate catalyzed by enzyme 
and chemiluninescent donor to QDs, respectively. The major advantages for those 
systems are low background noise and high excitation efficiency, as there is no need for 
an extra excitation source, typically high-energy laser. In this way, in particular, QD 
based BRET system has showed great potential in deep tissue imaging with low harmful 
effect on bodies.32 
 
 
Figure 1.1 Schematic illustration of FRET process 
Nanomaterials with special surface chemical properties can be used as a quenching 
energy acceptor incorporating in the FRET system. Au NP was used as a quencher for 
QD based FRET probe in a multiplexed assay in detection of the activity of enzymes and 
their inhibitors. 25  
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1.2 Limitations of using NPs in biomedical fields 
Despite that colloidal inorganic NPs offer immense promise for biomedical applications, 
several concerns remain to be addressed.  
The primary concern probably is the stability of NPs in water, as most biochemical 
process occurs in aqueous environment. However, generally used methods usually 
provide nanoparticles with hydrophobic ligands, meaning they are unstable in aqueous 
solution. Another important concerning is the potential health and safety issues while 
exploring nanomaterials to human body and environment. The determinants of particle 
toxicity are known to be the large surface area and chemical reactivity in relation to small 
size (and thus the ability to generate reactive oxygen species) and the capability to 
penetrate tissues and cells.34 Thus, particles in nano-scale are likely to be more hazardous 
than their bulk compartments, and free particles more toxic than fixed ones.35 One of the 
examples to be considered is the potential cytotoxicity of QDs, because the heavy metals 
core is toxicity, and particularly at high concentrations they could cause harmful effects 
on embryo development and cell viability and function.36 Lastly, a nanoparticle must be 
conjugated to a well-defined biological molecule, such as antibody, receptor, enzyme or 
nucleic acid, for targeting application. Hence, there exists a gap between the nature of 
NPs and their uses in biomedicine. 
One method to bridge such a gap is the surface functionalization of nanoparticles (Figure 
1.2). A proper surface coating can stabilize particles and avoid agglomeration, which 
hence may increase the sensitivity of NPs based sensor. In addition, a proper surface 
coating enables the nanoparticles in response specifically to biological species and avoids 
non-specific interactions with components in the complex matrix. Coating is also an 
effective manner of preventing the dissolution and release of core materials that may 
cause toxicity to biological system.37 Furthermore, the steric hindrance of coating can 
affect the fate of NPs in biological system, such as cellular uptake and accumulation, 
circulation and clearance from body.38-40 In addition, the surface can affect the 
maintenance of the intrinsic nanocrystal properties such as fluorescence and magnetic 
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behaviour. Moreover, appropriate surface functionality is the perquisite for conjugating 
biomolecules to NPs for biomedical applications.  
 
 
 
Figure 1.2 Strategy for bridging the unique feature of nanoparticles to biomedical 
applications. 
1.3 Aims and Objectives 
 In view of the above overview, the overall objective of current research projects is to 
design and develop advanced NPs with suitable surface for cellular imaging and 
biosensing applicatoins. Several goals are set up to fulfill the objective as showed below. 
(1) To develop hybrid fluorescent nanoparticles with unique proton resistant property 
for cellular imaging application. 
(2) To synthesize and prepare bioconjugated magnetic fluorescent nanoparticles for 
simultaneous capture, detection and deactivation of bacteria for infectious disease 
control. 
(3) To develop sensitive and fast responsible luminescent nanosensors for disease 
early diagnostics 
To achieve these goals, the following specific objectives are sought in various chapters of 
the thesis: 
• 
This chapter provides an overview of biomedical application of NPs, the outline 
of objectives and the layout of the thesis. 
Chapter 1: Introduction  
• 
This chapter presents a general review of strategies for surface functionalization 
and bioconjugation of colloidal inorganic nanoparticles. 
Chapter 2: Background and Literature Review 
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• 
This chapter presents preparation of biocompatible polymer-quantum dots hybrid 
nanocomposites and their potential application in bioimaging. Two approaches 
were developed to produce the nanocomposites. In particular, multiple layer 
coating NPs prepared by the second approach shows its advantages in stabilizing 
QDs luminescence in term of intensity and lifetime among different pH range. 
Chapter 3: Development of biocompatible luminescent nanoparticles for 
bioimaging applications. 
• 
This chapter describes preparation of antibiotic gentamicin functionalized 
fluorescent magnetic nanoparticles. The nanoparticles have a fluorescent 
silica/iron oxide core/shell structure. The gentamicin conjugated fluorescent 
magnetic nanoparticles shows an all-in-one method for capture, detection and 
deactivation of both Gram-negative and positive bacteria. 
Chapter 4: Development of bioconjugated magnetic luminescent nanoparticles for 
bacterial capture, detection and antibacterial applications. 
• 
Following the success of my developed advance nanoparticles, in this chapter, I 
extended the application of bioconjugated fluorescent nanoparticles into 
nanosensors. The detection manner is based on energy transfer from 
bioluminescence from enzyme catalytic reaction to gold nanoparticles. We found 
the nanosensor could detect thrombin at nano-gram range in 15 min from both 
buffer and human urine samples.  
Chapter 5: Luciferase conjugated nanoparticles for biosensing applications. 
• 
This chapter provides a general conclusion of the above studies and 
recommendations for future work on the surface modification and conjugation of 
the nanoparticles. 
Chapter 6: General discussion and recommendation. 
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2.1 Colloidal Inorganic Nanoparticles for Biomedical 
Application 
Colloidal inorganic nanoparticles (NPs) are small objects sized between 1 and 100 
nanometers (nm) that can be dispersed in a solvent. During the last two decades, colloidal 
NPs have been attracting considerable interest from a wide range of disciplines, including 
materials science, chemistry, physics, biology and engineering, because of their unique 
physical and chemical properties. The change in those properties at this length scale from 
their bulk counterparts can be attributed to a combination of scaling factors and nature 
material of the NPs. These NPs can be composed of various materials including noble 
metal, semiconductor, magnetic compounds and a hybrid of them. 
The biomedical utility of colloidal NPs can arise from a variety of attributes, including 
their physical properties such as optical (absorption or emission of light) and magnetic 
properties.1 In addition, as biological processes generally occur at molecule level, the 
similar scale of NPs makes it a suitable platform for investigating those processes. For 
example, biomacromolecules surface recognition by NPs offer a potential tool for 
studying transcription regulation, enzymatic inhibition, delivery, sensing etc.  
The aim of this chapter is to give a brief introduction of NPs of biomedical use and 
current strategies of surface functionalization and bioconjugation of colloidal inorganic 
NPs with a special focus the NPs with optical (semiconductor NPs, such as QDs) and 
magnetic properties.  
2.1.1 Noble metal NPs 
Noble metal NPs such as gold NPs and silver NPs are an important class of nanomaterials 
used in biomedicine due to their unique surface plasmon resonance (SPR) absorption. 
The SPR is caused by the interaction between incident light and oscillation of electron 
charge on the surface of NPs (Figure 2.1).  
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Figure 2.1 Schematic illustration of the SPR effect. The electromagnetic field of the light 
induces a coherent dipole oscillation of the metal conduction electrons across the 
nanoparticle (Adapted from Ref 2). 
The response of noble NPs to oscillating electric field can be described by Mie theory, if 
the diameter of a spherical NPs is much smaller than the wavelength of the incident light 
(λ).3, 4 As shown in equation 2.1, the extinction cross section (Cext) of a particle (radius of 
R), which defines the energy loss in the direction of incident light due to both absorption 
and scattering, is described in term of dielectric function of the metal (ε = ε’+ iε”) and 
dielectric constant of the medium εm.
3 For small size of Au NPs (<60 nm), the absorption 
cross section dominates in the Cext.5 
Cext = 24π2R3εm3/2λ  ε"�ε′+2εm�2+ε"2                          Equation (2.1) 
where ε = ε’ + iε” is the wavelength-dependent, complex dielectric function of the NPs 
material and εm is the dielectric constant of the surrounding/embedding medium.  
The frequency of SPR is thus dependent on the size and composition of NPs, as well as 
the dielectric constant of medium. The change in SPR frequency yields the change of 
NPs color that can even be observed through bare eye. The SPR frequency is strongly 
sensitive to the dielectric constant (ε) of the surrounding media, such as surface ligand 
changes and inter-particle aggregation. This great sensitivity makes Au NPs and Ag NPs 
well suited for bioassay applications. For example, analytes such as DNA, metal ions and 
antibodies can be detected by observing the visible color changes due to Au NPs 
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aggregation.6-8 Other examples are reviewed elsewhere including utilizing surface-
enhanced Raman scattering (SERS) for sensing.9, 10 In addition, the maximum 
wavelength of SPR absorption for Au NPs fall into the visible range (520 nm to 600 nm), 
which makes Au NPs as an excellent quencher to some common fluorophores for 
bioimaging and biosensing application via resonance energy transfer process.11  
Au NPs also find their applications in assisting drug delivery and therapy, due to the high 
absorption cross-section. For instant, Halas et. al., reported near-infrared light triggered 
gold nanoshells loaded hydrogels for deliverying a soluble drug.12 The mechanism is that 
heat generated from the absorption of light by Au NPs triggered the hydrogels to collapse 
and subsequently caused the release of the drug. Based on the similar concept, recently, 
functionalized Au NPs or Au-hybrid NPs have been shown as a versatile tool for 
photothermal cancer therapy 13, 14 and thermal ablation of pathogens.15 It is a great 
advantage for such applications operating at NIR region, a transparent window for blood 
and other types of biological samples.  
2.1.2 Semiconductor quantum dots 
Quantum dots (QDs) are semiconductive and fluorescent crystalline particles that 
typically have diameters ranging from 2 nm and 10 nm.  Semiconductors have a valence 
band filled with electrons and an empty conduction band separated by a band gap (Figure 
2.2). An electron in the valence band can be excited into the highest level of the 
conduction band by absorbing a photon with energy higher than the band gap energy, 
leaving a hole of opposite charge in the valence band. An electron and its hole are 
attracted towards each other by Coulomb force, and together form an exciton. The 
distance between the excited electron and its hole is called the Bohr radius. QDs 
fluorescence occurs when the excited electron reverts to its hole in the lowest level of the 
valence band and emits a photon with equivalent to the band gap energy (lower than the 
absorbed).  
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Figure 2.2 Size dependent photophysical properties of semiconductor quantum dots. 
As the diameter of QDs is in the same order as its exciton Bohr radius, the excitons are 
squeezed, leading to quantum confinement effect. The energy required to excite the 
electron can be estimated in equation 2.2,16, 17 
∆𝐸 = ħ2𝜋2
2𝑅2
�
1
𝑚𝑒
+ 1
𝑚ℎ
� −
1.786𝑒2
𝜀𝑅
− 0.248𝐸𝑅𝑦∗                     (Equation 2.2) 
where me is the free electron mass, mh is the hole mass, and ε is the size-dependent 
dielectric constant, R is the particle radius, ħ is the reduced plank constant and E*Ry is the 
effective Rydberg energy that is usually small. The first term is band gap energy obtained 
by “particle in a box” model. The second and third term indicate Coulomb force and 
spatial correlation effect, respectively. The implications of the equation are clear that the 
energy of the QDsare dependent on their size due to the quantum confinement effects. 
Typically, smaller particles exhibit higher band gap energy and blue-shift emission. 
The size-dependent fluorescent properties of QDs are superior to that of organic dyes in 
biomedical applications. Firstly, QDs possess broad absorption spectra while maintaining 
the same emission spectra. In addition, the emission profile is narrow and tunable, 
allowing for multiplexing labeling. Furthermore, the bright fluorescence and significant 
resistant to photobleaching, ensure a high ratio of signal to noise while applying them in 
imaging. 
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The pioneer work for utilizing QDs in biomedicine were reported by two groups in 1998, 
demonstrating water-soluble bioconjugated QDs as an excellent labeling agent for cell 
imaging.18, 19 Since then QDs have been tested in various biological applications due to 
its bright fluorescence, including DNA array technology, immunofluorescence assays, 
labeling in cell and animal biology.20 One benefit of using QDs as labeling agents is the 
ability to excite and detect several species simultaneously using one single light source.21, 
22 Besides severing as staining agents for bioimaging, QDs with bright fluorescence can 
be also used to study the dynamic process inside living cells at molecule level .23 Apart 
from directly labelling, the narrow emission profile makes QDs as excellent donors for 
FRET based sensing and imaging (see also in Chapter 1). In addition to imaging, QDs 
were also used as photosensitizing agents for photodynamic therapy (PDT).24  
2.1.3 Magnetic Nanoparticles 
Magnetic nanoparticles (MNPs) are a class of NPs, which commonly consist of magnetic 
elements such iron, nickel and cobalt or their chemical compounds. The magnetic 
properties in matter are generally the consequence of the response of electrons magnetic 
moments (due to their rotation around nucleus and spinning up and down) to an external 
magnetic field. As shown in Figure 2.3, the materials can be classified into three 
categories including diamagnetic (zero net moment, repelled by external field), 
paramagnetic (zero net moment, attracted by external field), or ferromagnetic (exist net 
moment, attracted by external field), depending on their response to an external magnetic 
field.25  
 
Figure 2.3 The responses of materials to magnetic field. 
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MNPs exploited in biomedical fields are commonly made of ferromagnetic materials. In 
such materials, the unpaired electron spins of an atom are interacting, leading to a parallel 
oriented magnetic moment and maintain a low energy state. The regions where the 
parallel orientation occurs are called magnetic domains. For energetic reasons, the size of 
the magnetic domain is usually smaller than the grain size. If the size of the magnetic 
materials is reduced when only one domain is reached (ranging from ~20 nm to several 
hundred nm), as in case of magnetic NPs, the magnetic behaviors are different from their 
bulk materials. 
In single domain particles, the electron spins rotate in unison, flipping the entire magnetic 
moment of particles coherently and leaving a net magnetization and preferred aligned 
direction. As the size of particle ( diameter d for spherical particles) is reduced, the 
coercivity (Hc), which is the intensity of the applied field to overcome this magnetization, 
drops to zero at the superparamagnetic limit dsp (typically less than 40 nm). In such a 
case, particles that were originally aligned will have random directions at the 
measurement time without external field, due to thermal fluctuations of energy kBT (kB is 
Boltzman constant, T is measure temperature). For the same particles, their magnetic 
behavior can be affected by temperature. If the superparamagnetic particles are cooled, at 
certain temperature, the measurement time will be insufficient for complete magnetic 
relaxation, i.e. the particles will exhibit hysteresis (Hc >0). This temperature is known as 
the blocking temperature (Tb). For example, TB of 26 nm Fe3O4 NPs is about 300 K 
(room temperature). Therefore, particles large than ~26 nm are predicated to exhibit 
ferromagnetism, while smaller ones should have superparamagnetism.26 
Blocking temperature can be affected by particle size. The relationship between them can 
be obtained from Equation 2.3,27 
𝑇𝐵 = 𝐸𝑎𝑘𝐵 ln𝑓𝑡                                        (Equation 2.3) 
Where t is the experimental measuring time, Ea is the anisotropy energy barrier that the 
magnetization flip has to overcome by thermal energy. The term in the denominator can 
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be treated as constant. Ea = KV, where K is the anisotropy energy density constant and V 
is the volume of particles. Thus, blocking temperature is size dependent. 
Superparamagnetic NPs, in particular iron oxide MNPs, are widely designed for pre-
concentration, separation, and identification of molecules and specific biological units 
and are particularly suitable for integration in micro fluidic devices.28, 29 Additionally, the 
advantages of a very large surface area and good biocompatibility make these NPs 
suitable for integration with biological system.  
The most important utilization of MNPs is separation and targeting of analytes. 
Numerous reports took the advantage of immuno-separation by antibody functionalized 
MNPs in detection of bacteria. In one example, Mujika and co-workers reported a 
magneto-resistive immunosensor for the analysis of Escherichia coli O157:H7 in food 
and clinical samples. This biosensor enabled to detect and quantify small magnetic field 
variations caused by the presence of superparamagnetic particles bound to the antigens 
previously immobilized on the sensor surface via an antibody–antigen reaction.30 
However, different methods for detection of MNPs become more and more important 
while incorporation with immuno-separation. Other common reported detection methods 
are impedimetric measurements 31 and electrochemical magneto-genosensing.32 In the 
latter case, Liebana and colleagues reported the integration of immunomagnetic 
separation/double-tagging PCR/electrochemical magneto-genosensing to detect 
Salmonella in skimmed-milk samples with a limit of detection (LOD) of 1 colony 
forming-unit (cfu)/mL. By combining the magnetic separation and miniature technology, 
individual cells can now be separated through a microfluidic device system and 
visualized in a low power microscopy.33 Another important aspect for taking the 
advantage of magnetic attraction property is the transport of drugs and gens by magnetic 
NPs. MNP medicated drug delivery can be performed via passive, active or direct ways.34 
Research work about the functionalization of MNP with emphasis on the active in vitro 
or in vivo drug delivery and related recent clinic results are reviewed by Pankhurst et. 
al.35 
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In addition to separation and identification of target from matrix, MNPs have recently 
been used as labels in biosensing and bioimaging. For example, Koets and co-workers 
reported using streptavidin-coated superparamagnetic particles as detection labels for E. 
coli and Salmonella via a Giant Magneto Resistance (GMR) sensor.36 An important use 
of MNPs now is for magnetic resonance imaging (MRI) application where the NPs are 
introduced as contrast-providing agents which have been summarized elsewhere.37-40 
Despite of few examples, MNPs can also be used as antiseptic agents. There are main 
two methods to modify magnetic NPs to obtain the antimicrobial NPs. The first one is to 
functionalize NPs with biomolecules of antimicrobial activity. For example, in the study 
conducted by Kaittanis, C. et. al., Con A-conjugated polysaccharide magnetic NPs have 
been shown with significant and fast inhibition of the growth of E. coli and S. marcescens 
in blood culture.41 In another work, Chen et. al. reported that the immobilization of 
antimicrobial peptide LL-37 on the surface of polyacrylic acid coated NPs can effectively 
kill E. coli.42 The second method to enable magnetic particles with antimicrobial 
properties is to coat them with inorganic/organic antibacterial layers. For instance, silver 
NPs and TiO2 layer have been deposited onto the surface of magnetic particles to produce 
antibacterial agents.43, 44 
2.2 Synthesis of colloid NPs for biomedical use 
Colloidal inorganic NPs can be synthesized by various physical and chemical methods, 
with the particles differing in their elemental composition, shape, size and chemical or 
physical properties.45 The physical methods in general involve vapor deposition 
approaches which dependent on sub-dividing of bulk materials to smaller NPs. Typical 
chemical ways involve the reduction of ions into atoms in the presence of stabilizing 
agents, followed by controlled growth of atoms into NPs (so called “bottom-up” 
process).46 In the case of biomedical applications, solution based chemical synthesis 
methods have been proved preferable ways, as they are more effective to control the size 
distribution and ready for further modification or conjugation with biological species. In 
this way, as-synthesized NPs are dispersed in a solvent either water- based or an organic 
solvent for hydrophilic or hydrophobic particles, respectively; meanwhile amphophilic 
NPs can be dispersed in both kinds of solvents.  
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2.2.1 Synthesis of NPs in water 
A variety of NPs including Au, 47, 48 Ag,49 Co,50 Fe3O4,35 Fe2O3,51 SiO2 52 and CdTe 53, 54 
have been synthesized in aqueous solution. These methods produce water-dispersible 
NPs, a necessity for the application in biological systems. One typical example is the 
synthesis of noble metal NPs such as Au NPs by reduction of Au(III) salts using reducing 
agents such as sodium citrate, citric acid, ascorbic acid or amines.55 In addition, 
biomolecules (e.g. starch) are also used as reducing agents providing a green protocol. In 
another way, aqueous co-precipitation process, which involves nucleation growth, 
coarsening and /or agglomeration, has been widely used in preparation of metallic and 
metal (hydr) oxides NPs. The composition and morphology of the NPs are controlled by 
precisely adjusting the reaction parameters.56 Stöber method, an aqueous sol-gel process, 
is established to synthesize SiO2 NPs.52 Success has also been achieved in synthesis of 
water-soluble semiconductor CdSe and CdTe quantum dots.54 However, limits in 
controlling a narrow size distribution and low ordered crystalline structure remain as 
main challenges, which subsequently affect their physical properties and stabilities. 
2.2.2 Synthesis of NPs in organic phase 
NPs composed of noble metals, transition metals, oxides and semiconducting materials 
have been synthesized in organic phase via a thermal decomposition process. The process 
general involves high temperature thermolysis of metal-organic precursor in the presence 
of a hydrophobic capping agent, as well as in a non-polar organic solvent. The resultant 
NPs usually gain high quality of nanocrystals.57 The growth of NPs, the crystal structure 
and the cessation of growth depend on the environment and are fundamentally regulated 
by the hydrophobic ligand. These ligands are either surfactant species such as fatty acid 
or alkane thiols. The obtained NPs are thus inevitably hydrophobic. The ligands in some 
cases also serve as solvent. One example is using tri-n-octyl phosphine oxide (TOPO) for 
capping the semiconductor quantum dots.58 
Hydrophilic NPs can also be produced in one-pot synthesis in organic phase by using 
dedicatedly selected stabilisation ligands. For instant, amphiphilic ligands such as 
peptides 50 and thermo-responsive polymers 59 have been used in preparation of Co NPs. 
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However, only few examples have been reported due to the limit of amphiphilic 
materials. 
2.3 Surface Functionalization of NPs 
A large portion of NPs used in biomedicine is produced in organic phase through high 
temperature process. High-temperature synthesis in organic phase offers a number of 
advantages over aqueous synthesis. Firstly, high temperature allows the impurities of NPs 
be annealed out to obtain good crystallite structure. Furthermore, long chain of organic 
ligands enables steric stabilization of NPs and allows higher concentration of NPs to be 
produced. Moreover, temperature can be used to manipulate the morphology and size of 
the NPs through controlling the growth kinetics of crystals. However, the resultant NPs 
with apolar ligand are only soluble in organic solvents, e.g., hexane, toluene or 
chloroform. They usually cannot be used directly for most applications in biomedicine, as 
most biological process occurs at aqueous environment. Therefore, it is necessary to 
bring them with water solubility, prior to the use them in biomedicine. One method to 
circumvent this problem is development of strategies for surface functionalization of 
NPs. Such strategies should satisfy certain criteria: i) they can enable NPs with good 
water solubility, ii) they should offer a reduction of toxicity of NPs in some instances, iii) 
they can provide additional functionalities for further conjugation of biomolecules for 
targeting applications, and iv) they can stabilize the physical properties of NPs. Here a 
variety of strategies for surface functionalization of NPs are evaluated and compared to 
their effect on parameters relevant to stability, nonspecific binding, and biocompatibility 
of NPs. The discussion falls in three categories: ligand exchange, ligand modification and 
ligand addition (encapsulation), as shown in Figure 2.4. 
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Figure 2.4 Schematic illustrations of common surface functionalization strategies.  
2.3.1 Ligand exchange 
For biomedical applications, ligand exchange of NPs usually involve a process that the 
initial hydrophobic ligands are replaced by other more strongly bonding hydrophilic 
ligands that allow the transferring of NPs from organic phase to aqueous solution. A 
number of hydrophilic ligands have been reported to exchange the nature ligand on the 
surface of NPs and bring them to aqueous solution, including small molecules with 
functional headgroups (e.g. thiol, carboxyl, amine, phospine group, etc.), PEG derivatives 
and biological molecules (Figure 2.5). 
Small molecules. Small molecules with high affinity head functional group are primary 
candidates for generating water-soluble particles, as they produce NPs with a smaller 
hydrodynamic radius, which promotes in vivo trans membrane permeation and excretion 
of NPs.60 Common examples of small molecules are alkylthiol terminated molecules that 
can strongly bind to the inorganic surface of NPs, e.g. Au and Ag 61 or CdSe QDs,18, 62-65 
by replacing weaker ligands. However, the colloid stability of the resultant NPs in buffer 
solution is often poor which is partially attributed to the desorption of ligands from 
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NPs.64 To overcome this problem, bidentate ligands such as dihygrolipoic acid (DHLA) 
and dithiocarbamate ligands are used to stabilize the NPs by increasing the number of 
anchor points to particle surface.66-68 In addition to alkyl thiol terminated ligand 
molecules, many molecules with other functional headgroups have also been developed 
to transfer NPs from organic phase to aqueous solution. Excellent examples include 
tetraalkylammonium salts such as tetraoctylammonium bromide (TOAB) for transfer of 
AuNPs, and hexadecyltrimethylammonium bromide (CTAB) for iron oxide NPs;69, 70 
oligomeric phosphine (oxide) ligands for transfer TOP/TOPO capped QDs;71 amphiphilic 
species such as 2, 3-dimercaptosuccinic acid (DMSA) 72 and cyclodextrin 73 for 
transfering of oleic acid capped NPs, respectively. However, one drawback is that the 
small ligands rely on electrostatic interaction to stabilize NPs. Therefore, when the 
solution condition such as pH and salt concentration changed, the NPs may be “salting 
out” and forming aggregation.  
 
 
Figure 2.5 Common ligands for stabilizing NPs in water. 
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PEG derivatives ligands. An alternative is using polymeric ligands as ligand exchange 
agents to overcome the poor colloidal stability of NPs that capped by small molecules. A 
number of polymers have been reported to offer NPs with good stability and water 
solubility. Among them, poly (ethylene glycol) (PEG) is the most common reported 
ligands for stabilizing NPs especially in biomedical applications. The ether group in the 
backbone of PEG chains utilizes hydrogen bonding and steric stabilization for water 
solubility, instead of electrostatic interactions. It is thus expected that PEG based NPs 
would confer well stability over a wide pH range and even at high salt concentration. 
Taking advantage of this, Mattoussi’s group developed a set of DHLA-PEG derivatives 
for capping QDs through ligand exchange.74, 75 As a result, by combining the benefit of 
strong bonding through dithiol moiety to particle surface, the PEG based QDs confer 
water solubility over a wide pH range and high salt concentration. In addition to good 
particle stability, PEG based NPs also were also found with low degree of nonspecific 
binding to biological components, less cytotoxicity and longer circulation time in vivo.76, 
77 Due to those advantages, it has been now increasing common to use PEG segments for 
capping NPs to improve the biocompatibility.78 However, it should note that PEG itself is 
simply a polyether, in general it should be modified with reactive terminal functional 
group to serve as an anchor to the NPs. 
Biomolecules. Other exchange ligands involved are biomolecules such as sugars, peptide, 
nucleic acid and their derivatives. In one example, glucose and sucrose have been used in 
reduction and post-synthesis stabilization of Ag and Au NPs in aqueous salts.79 Small 
peptides are also used as QDs surface ligands. Pinaud and co-workers developed 
phytochelatin-like peptides replacing TOPO for coating CdSe/ZnS QDs.80 The advantage 
to use peptides as surface ligands is they offer an all-in-one solution for particles 
solubilisation and biofunctionalization. Several other examples will be discussed in the 
biofunctionalization part. 
2.3.2 Ligand modification 
A different strategy from ligand exchange is in situ modification of ligand for phase 
transfer, which can prevent NPs aggregations due to irreversible desorption of replaced 
ligands. This strategy can be achieved by either modifying a compound that can change 
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the polarity (e.g. oxidation of oleic acid to form carboxyl group or vicinal diol 81), or 
addition of hydrophilic agent which can interact with the hydrophobic ligand (e. g. 
formation of a complex of cyclodextrin with oleic acid,73 or covalent conjugation with 
amphiphilic agents (e. g. conjugation with V-shaped ligand 82). Despite of high efficient 
phase transfer, this concept is merely limited to certain systems. 
2.3.3 Ligand addition 
Ligand addition involves an addition of the external surface of the NPs shell without 
removal of any initial ligands. The strategies include addition of a layer of inorganic 
materials and encapsulation of a layer by intercalating hydrophobic polymers into the 
initial hydrocarbon shell of NPs. 
Inorganic core-shell structures. One of the major challenges for functionalizing NPs is 
find a common agent/ligand for ubiquitously capping the NPs. However, as for organic 
molecules capping, it is necessary to select specific head groups of ligands that have high 
affinity the NP core. This will limit its applications. Alternatively, coating NPs with an 
inorganic layer/shell for which the ligand has a high affinity is of great interesting. 
Materials, such as noble metal (Au and Ag), semiconductor (e.g. ZnS) and silica, have 
been used as NP shell to protect the core, add functionality or introduce chemical group 
for further functionalization. 
Probably, one of the most widely used methods for surface coating of NPs is silica 
coating. The advantages silica coating includes enhanced water soluble, good colloidal 
stability, low non-specific interaction and biocompatibility.83 A typical process to grow a 
silica shell around NPs involves firstly exchanging of hydrophobic ligands with primer 
molecules, such as 3-(trimethoxysilyl) propyl methacrylate (MPS) and 3-aminopropyl-
triethoxysilane (APTS) by selection of the precursors specific for each NP material. Then 
the growth of a amorphous silica shell can be processed via hydrolysis of sodium silicate 
(Iler process) or tetraethoxyxillane in alcohol (Stöber method).84, 85 A modified method 
involving the base-catalysed hydrolysis of tetraethyl orthosilicate (TEOS) has now been 
widely used. One advantage of this method is the capability of controlling of silica shell 
thickness by simple adjusting the ratio of component in the reaction mixture 
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(ethanol:water).86 The pH is very important for hydrolysis of TEOS. Mildly alkaline pH 
(7.5) is found as the optimum point for formation of core-shell structure.  
Using the same chemistry, secondary silanes with ionizable hydrophilic groups can be 
introduced on the initial silica shell to render NPs hydrophilic or add chemical 
functionality. For example, incorporation of PEG chains can improve the stability and 
biocompatibility of the silica coated NPs. Functionalization with APS and MPS can 
facilitate the covalent binding with biomolecules through amine and thiol group, 
respectively. Mesoporous silica can also grow on the surface of NPs, just after the 
formation of a thin layer of amorphous silica as describe above. Cationic surfactants such 
as CTAB have been used as templating materials to synthesize mesoporous silica shell on 
NPs surface.69, 87-89 The mesopores allow loading of drugs such as doxorubicin and 
ibuprofen to serve as devilry cargo.89, 90 
So far, the silica shell have been successfully deposited on a variety of colloidal particles 
of metals,84, 91-93 metal oxides,94, 95 and semiconductors.19 However, the growth of silica 
shell in general results in increasing of the hydrodiameter of the NPs, which consequently 
may affect the physical properties of NPs, e.g. deterioration of saturation magnetisation 
whiling coating magnetic particles.96 In addition, polymeric silica present in the NPs 
surface can cause NPs aggregation by slow hydrolysis process without further surface 
modification.97 
Polymer encapsulation via hydrophobic interactions. Polymer encapsulation involves 
over-coating hydrophobic ligand capped NPs with amphiphilic polymers. The 
encapsulation is achieved by intercalating the hydrophobic portion of polymer with the 
initial ligand on the NPs surface and rendering hydrophilic portion towards the solution. 
Head groups, such as carboxyl or amine groups, and/or PEG segment within the 
hydrophilic portion of the polymer, bring NPs water solubility. The functional group can 
further allow for bio-conjugation or bio-modification of NPs. Initially, phospholipids, 
which can form micelles with 5 nm hydrophobic interior, were used to over-coat TOPO 
capped NPs and render them water-dispersibility.98-101 However, the resultant NPs 
suffered from poor stability because of desorption of the relative weak anchoring 
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phospholipids from the NPs. To improve the stability, low water-soluble fatty acids were 
used to generate lipid bilayers coated NPs.102 An alternative is using amphiphilic co-
block polymers, of which a single polymer contains multiple hydrophobic side chains to 
enforce the hydrophobic interaction. Wu et. al., developed a co-block polymer for coating 
TOP/TOPO capped QDs.103 The strategy involves appending a poly(acrylic acid) (PAA) 
back-bone by hydrophobic octylamine chains through EDC mediated conjugation, 
following by coating to QDs. In their report, 40% of the carboxylic group of on the PAA 
back-bone were converted by hydrophobic alkyl chain. The octylamine chains then 
intercalated into hydrophobic TOP/TOPO ligands on the QD surface, and the remaining 
negative carboxylic groups could then promote the particle water-soluble. Some other 
amphiphilic co-polymers such as poly(maleic anhydride aIt-1-tetradecene) 104 and 
PEGylated polymer 105, 106 were also reported to generate hydrophilic QDs. The 
significant advantage of using polymer coating is that, theoretically, a wide range of 
different NPs can be transferred into water with one optimal amphiphilic polymer. The 
over-coated NPs in general can also benefit from excellent colloidal stability over a wide 
pH rang and at high salt concentrations.   
2.4 Bioconjugation 
Surface functionalization can render NPs water-solubility, functionality and stability in 
physiological environment. After that, NPs are required to conjugate with biomolecules 
of interest (e.g. small bioactive molecules, peptide, proteins, nucleic acid, etc.) for further 
biomedical applications. Many conjugation strategies have been developed. Here some 
common used methods are discussed below (Figure 2.6).  
2.4.1 Direct absorption 
Biological species can interact directly with different kinds of NPs. Non-specific staining 
of certain celluler structure may be achieved by injecting hydrophilic NPs into 
cytoplasm.107 The NPs even without additional functionalization have been shown to 
attach to certain place inside cell.108 However, the interaction is usually weak and non-
specific, and has limited uses. Instead, the signal generated from non-specific interaction 
may interfere with the real measurement. Thereby, the direct absorption of biomolecules 
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by NPs mentioned here refers to the specific attachment of certain biological molecules 
to NPs with relative strong non-covalent interaction. 
Biomolecules with special functional groups can be directly linked to NPs. For examples, 
thiol groups from cytosine amino residue can be used to coordinated peptides or proteins 
to noble metal NPs 109 and QDs.110 Similarly, DNAs oligos terminated with thiol group 
have also been labelled to those NPs.63, 111, 112  Furthermore, metal-affinity driven self-
assembly is also utilized for the conjugation of biomolecules to NPs. One example is 
polyhistidine (six histidine residues) tags (His tag) can allow strong and reversible 
conjugation of proteins or peptides on the Ni-nitrilotriacetic acid (Ni-NTA) modified 
NPs.113-115 More interesting, His tag appended protein were also found to directly 
coordinate with the metal zinc ions of the ZnS coated QDs.116 
A different approach is the absorption of biomolecules to NPs surface via electrostatic 
interactions. For instant, negatively charged nucleic acid can be attached to the positive 
charged surface of NPs.117, 118 Proteins, which have a natural positive (or negative) charge 
under physiochemical environment, can also adhere to NPs with negative (or positive) 
charges. Others neutral charged proteins could be engineered with charged domain to 
enhance the adsorption to NPs surface. Mattoussi et. al., have engineered maltose binding 
protein (MBP) 66 and protein G with a positively leucine zipper domain.119 The 
engineered proteins can then adhere to the surface of DHLA capped QDs. As the 
attachment is mediated by electrostatic interaction, the conjugation is simple dependent 
on the surface charge of NPs, regardless of the material of NPs. There are, however, 
some drawbacks with this approach, including sensitive to pH and salt concentration, 
high degree of non-specific binding, and required engineering of proteins in some cases.  
2.4.2 Covalent coupling 
Covalent coupling provide specific and stable conjugation of biomolecules with NPs. 
Typically, functional groups on the NPs surface including carboxylic group, amide group 
and thiol group can cross-link with biomolecules through various coupling strategies 
(Figure 2.6). Some common strategies are discussed below based on the functional 
groups involved. 
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Figure 2.6 Representative bioconjugation protocols. 
Amine group involved coupling. Probably the most commonly coupling methods for 
bioconjugation of NPs involve amine functional group. Primary amine can react with 
carboxylic group to form a “zero length” amide bonds. The linkage is usually mediated 
by carbodiimide agents, such as most commonly used 1-ethyl-3-(dimethylaminopropyl) 
carbodiimide (EDC) (Figure 2.7a). The conjugation strategy has been applied to coupling 
of various proteins (e. g. enzyme and antibodies) ,18, 120-125 amine-terminated nucleic 
acid,124, 126 small molecules with amine groups,127, 128 etc., to carboxylic group 
functionalized NPs. Few cases are also found between amine functionalized NPs and 
carboxylic groups on biomolecules. More specifically, the coupling efficiency can be 
enhanced by addition of stabilising agents such as n-hydroxysuccinimide (NHS) or sulfo-
NHS by formation of a succinimide ester intermediate.129 A variation of this strategy is 
using bis-NHS to cross-link two amines group.130  
In addition to carboxylic group, the active nucleophilicity allows amine group to react 
some other functional groups, such as aldehydes, thiol group, epoxides and isocynates. 
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For example, glutaraldehyde was used to conjugate enzymes to NPs surface by bridging 
two amines from each species.131 The space of the linkage is approximately 0.7 nm.132  
Thiol group involved coupling. The thiol group can selectively conjugate with primary 
amine groups. The reaction starts rapidly under the mediation of reagents such as 
maleimides and iodoacetamides.133, 134 Most commonly, the coupling reagent is 
sulfosuccinimidyl-4-(maleimidomethyl) cyclohexane-1-carboxylate (sulfo-SMCC) 
(Figure 2.7b). To take advantage of this reaction, amine-functionlized NPs can be 
conjugated with various thiolated biomolecules, including thiol modified peptide,135 
residue thiol-teminated DNA,107 or peptides and proteins with free or reduced cysteine,136 
or verse vice.137, 138 Disulfide bridges can be also used for reversible coupling of NPs. By 
utilizing of glutathione (GSH) disulfide and dithiothreitol, Tian et al., showed reversible 
oxidation and reduction of disulfide bridges between silica NPs and Fe3O4 NPs,139 
respectively. The same approach was adapted for delivering and releasing of drug via 
hybrid nanostructures, under the regulation of GSH.140 
Click chemistry. Another common approach for bioconjugation is the so called “click 
chemistry”. The reaction basically involves coupling of alkyne to an azide giving a 1,2,3-
triazole ring under catalyst of Cu (I). The process has been demonstrated to be highly 
versatile and great potentials for bioconjugation of NPs.141 The one-step click process has 
also been shown to give the possibility of introducing multiple functionalities onto 
NPs.142 The limitation probably is that it requires special preparation of the azide or 
alkyne-functional bioactive species, which is often involved a labor work and has low 
yielding.143 Fortunately, now many commercial kits have been developed to simplify the 
process and improve the products yield.144 
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Figure 2.7 Reaction scheme for EDC-NHS crosslinking (a) and (b) SMCC mediated 
conjugation.  
2.4.3 Biological approaches 
Biological processes are often completed by highly specific interactions of biomolecules, 
such as antibody-antigen interaction, receptor and target interaction, enzyme and 
substrate interaction, and complementary base pair of nucleic acid. It is thus possible to 
take the advantages of those high specific interactions for bioconjugation of NPs. For 
example, single oligo DNA functionalized NPs were used to specific recognize target 
genetic materials.145, 146 Furthermore, DNA aptamers functionalized Au NPs were 
reported to bind and response to different of analytes.147 Moreover, protein G 
functionalized NPs have been used to immobilize IgG via interactions with Fc region of 
the antibody, leaving the free Fab region for capturing staphylococcus bacteria.148 One of 
the most common used biological interaction is the (strept)avidin-bintin interaction which 
has a very high affinity (Kdiss > 1.3 x 1015 M). NPs can firstly functionalized with 
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(strept)avidin via either electrostatic absorption or covalent coupling methods. After that, 
the NPs can then used to label biotinylated peptides, proteins, antibodies and DNA.121, 149-
152 Antibodies and receptor/ligand biomolecules require a binding domain to be exposed 
and accessible in order to be biological active. However, even taking advantages of high 
specific interaction and high efficiency covalent coupling strategies, it is still a problem 
to control the orientation of biomolecules attached to NPs.   
To overcome the problem, recently expressed protein ligation (EPL) attracts some 
interesting as it allows for site-specific conjugation of targeting molecules to NPs. EPL 
refers to a native auto-processing chemical ligation mediated by a protein called intein in 
biological system. The process involves a recombinant protein with a C-terminal thioester 
and a second agent with an –N-terminal cysteine. This C-terminal thioester is usually 
introduced by intein which can be cloned downstream of the target protein (Figure 
2.8).153 A transthioesterification reaction occurs between thioester and amine of the 
cystein, followed by a rapid S → N acyl transfer to form an amide. Several studies have 
shown the versatile of EPL for site-specific bioconjugation of hydrazine nucleophiles 
modified NPs with engineered proteins.154, 155 However, as the efficiency of the 
conjugation depends on high concentration of both functional groups, it is relatively low 
while applied in NPs conjugation due to low concentration of NPs used. To overcome 
this problem, a two-step strategy was developed, which involvs ligation of azide (alkyne) 
modified small nucleicphilic molecule with engineered protein by EPL, and followed by 
conjugating of the azide (alkyne) linked protein with alkyne (azide) modified NPs via 
click chemistry.156, 157 It is expect that this EPL can offer great opportunities for 
conjugation of NPs with various enzymes or other proteins, particularly for biosensing 
applications. The limitation is that it is still required to genetically modify proteins by 
recombinant DNA technology.  
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Figure 2.8 Mechanism of intein mediated bioconjugation. 
2.5 Summary 
Surface functionalization of NPs is considered as a prerequisite for their biomedical 
applications. In general, an ideal surface should satisfy criteria such as providing good 
water stability and chemical functionality for further functionalization, maintaining NPs 
physical and chemical properties, and biocompatibility. Through the approaches 
discussed above, ligand exchange involves a simple process, even without affecting the 
particles size. However, it often compromises the stability of NPs, as the ligands tend to 
dissociate from the surface leading to the particles aggregation. In the case of QDs, the 
dissociation of ligand can result in decreasing of fluorescence efficiency. Polymer 
encapsulation is of great advantage, as it results in better stability and preservation of NPs 
physical properties (e.g. magnetization and photoluminescence). However, additional 
steps are required for formation of polymer and hydrodiamter of polymer coated NPs is 
usually large. In addition, the universal amphiphilic polymer to coat a wide range of NPs, 
though possible, is still under research. Incorporation of PEG backbone can increase the 
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biocompatibility. The drawback, however, is that encapsulation increases the particle size 
significantly. Therefore, it remains a challenge to satisfy all the criteria.  
On the other hand, directly coating peptide and protein on NPs are not often used, which 
could achieve relative small hydrodynamic diameter of NPs. For example, absorption 
relying on type of NPs and biomolecules with certain groups; meanwhile, electrostatic 
assembly requires strict physiological conditions, to avoid dissociation and nonspecific 
binding. Covalent bioconjugation approach probably is the most widely used 
bioconjugation method as it forms stable linkages. However, the stoichimetry of 
NPs/biomolecule is hard to control and it may cause self-assembly and biomolecules and 
aggregation of NPs. In addition, the controlling of the orientation of biomolecules 
immobilized to the surface of NPs is still a challenge. While biological affinity based 
methods, such as antibody/antigen conjugation, offer highly specific interaction, the 
drawback is it often leads to a large structure. Small protein mediated conjugation is 
attractive, as the reaction is highly selective, similar to enzyme catalysis.  The efficiency 
may need to improve. It is anticipated that these biomacromolecules (such as enzyme or 
bio-molecules likewise) will be promising agents for biofunctionalization of NPs in 
future, just like they work inside of biological systems. 
Therefore, the challenges remain in development of proper strategies in surface 
functionalization and bioconjugation of NPs with enhanced chemical and physical 
properties for desired applications in biomedicine.  
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CHAPTER 3 
DEVELOPMENT OF BIOCOMPATIBLE LUMINESCENT 
NANOPARTICLES FOR BIOIMAGING APPLICATIONS 
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3.1 Introduction 
Group II-VI semiconductor nanocrystals, referred as quantum dots (QDs), have been 
extensively studied as light-emitting materials for biological labeling over last decade, 
because of their strong size-tunable bandgap luminescence.1-4 Cadmium Selenide (CdSe) 
QDs are one of the most attractive QDs in bio-imaging due to their size-dependent 
emission in a visible region as well as the high photoluminescence (PL) quantum yield,5, 6 
However, CdSe QDs show the inherent biological toxicity 7, 8 and instability in aqueous 
solution,9 which limit their in vitro and in vivo biomedical applications. A variety of 
materials have been used to cap or re-cap QDs, including amphiphilic molecules,2, 10-14 
polymers 15, 16 and inorganic silica shells,1, 17, 18 to enhance the stability and 
biocompatibility of QDs. In particular, encapsulation of QDs in biopolymer not only 
protects QDs from oxidation, but also provides a biocompatible layer to avoid the direct 
interaction between living cells and the Cd- and Se- containing QDs core. In addition, a 
great variety of functional groups could offer new chemical functionalities to QDs by 
grafting bio-molecules.  
Gelatin is a natural biocompatible biopolymer derived from collagen. Gelatin 
nanoparticles (GNPs) have been used in gene delivery.19-21 Most recently, fluorescent 
GNPs-encapsulating demonstrates the potential applications in drug delivery and bio-
imaging at the same time.22-27 Unlike loading organic dye, loading quantum dots (QDs) 
within GNPs may improve the biocompatible of QDs and fluorescence properties of 
GNPs. The two-step desolvation process initially developed by Coester et. al. is able to 
produce well-tailored GNPs in terms of uniform size and narrow size distribution.20, 28 
Previous reports indicate that the pH value above 3.0 may result in early agglomeration 
of gelatin chains in the second-step of desolvation method.28, 29 However, it should be 
noted that the PL properties of QDs in terms of PL intensity and lifetime normally decay 
in acidic conditions, pH < 5, due to acid etching 10, 30 and/or surface state energies 
modification.31-33 In this case, encapsulating QDs into GNPs by the desolvation method 
might result in the quenching of QDs because of low pH value in the second desolvation 
step. In addition, other defects such as colloidal instability and low quantum yields (QY) 
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are hardly avoided in reported methods, e.g. in situ loading QDs onto GNPs in aqueous 
media.22, 26 
In this chapter, two approaches were presented for preparing hybrid CdSe QDs-gelatin 
nanoparticles (QDs-GNP) nanosystem. In the first method, nanosystem QDs-GNP1 is 
prepared by directly encapsulating hydrophilic CdSe QDs in NPs () via desolvation 
method through carefully controlling of the medium pH. Fluorescent property and 
biocompatibility were investigated. To improve the stability of QDs photoluminescence, 
a second approach involving an electrostatic layer-by-layer (LBL) deposition process was 
developed to prepare a novel multilayer gelatin/QDs core/shell NPs by assembly of 
hydrophilic CdSe QDs on the surface of gelatin nanoparticles (i.e. nanosystem QDs-
GNP2). The advantage of using electrostatic LBL deposition method is that it has been 
known as one of the simple and cost-effective methods for multilayer coatings.34-38 The 
sequentially assembled polymers with opposite charges onto micro/nanoparticle 
templates have demonstrated a great potential in fabrication of multifunctional core-shell 
structures.34 The morphology, structure, pH stability in term of PL property, 
biocompatibility, and potential applications in bio-imaging of the nanocomposites were 
further investigated, respectively. The PL properties of the core-shell nanoparticles as a 
function of the pH value are studied. In addition, the cytotoxicity of the luminescent 
QDs-GNP2 has been investigated by using NIH/3T3 mouse fibroblast cell line. It is 
expected that the new fluorescent core-shell QDs-GNPs can be an alternative fluorescent 
contrast agent with stable photostability and superior biocompatibility. 
3.2 Experimental procedures 
3.2.1 Materials and Reagents 
Type A gelatin from porcine skin (~300 g Bloom), cadmium acetate hydrate, selenium 
powder (99.5%), trioctylphosphine Oxide (90%, TOPO), trioctylphosphine (TOP, 90%, 
Aldrich), 11-Mercaptoundecanoic acid (MUA), tetramethylammounium hydroxide 
pentahydrate (TMAHP, 97%, Sigma), ethyl acetate, ether, poly(sodium 4-
styrenesulfonate) (PSS), polydiallyldimethyl ammonium chloride (PDAC), 
glutaraldehyde (25%), 2-(4-amidinophenyl)-1H-indole-6-carboxamidine (DAPI), and 
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phosphate buffered saline (PBS, tablet) were purchased from Sigma-Aldrich (ST, Louis 
MO). MultiTox-Fluor multiplex cytotoxicity kit was ordered from Promega (Madison, 
WI). For cell culture, Gibco® Dulbecco's Modified Eagle's medium (DMEM) and FBS 
were supplied by Invitrogen (Grand Island, NY). Glass bottom petridishes were supplied 
by MaTek Inc (MA, USA). 
3.2.2 Preparation of hydrophilic CdSe QDs 
TOPO capped CdSe QDs were synthesized following a modification of procedure 
described by Aldana et. Al.39 In brief, 0.5 g cadmium acetate hydrate mixed with 40 g 
TOPO was heated to 330 oC under argon flow. A selenium stock solution consisting of 
0.8 g selenium powder, 20 g TOP and 0.35 g anhydrous toluene was then injected rapidly 
into the above mixture. The temperature was cooled down to 270 oC and maintained for 4 
min. After that, the solution was cooled down to 30-50 oC.  Excess amount of methanol 
was added to the mixture to precipitate the QDs. The QDs were then centrifuged at 8000 
rpm for 15 min. After repeating washing with methanol and acetone, the hydrophobic 
CdSe QDs were dissolved in hexane and kept under dark.  
The hydrophilic CdSe QDs were prepared by replacing TOPO from the surface of QDs 
with MUA. In a typical experiment, 20 mg of MUA was mixed with 15 mL methanol 
under dark conditions and argon flow. The pH of the mixture was then adjusted to 10.3 
by addition of 200 mg TMAHP. Following that, 20 mg of the as-synthesized CdSe QDs 
were added into the mixture. The mixture was further heated to 65 oC. After overnight 
refluxing, the mixture was cooled down to room temperature. The QDs were then 
precipitated by addition of excess amounts of ethyl acetate and ether (1:1). The QDs were 
further washed and purified by centrifugation (5800 rpm for 5 min). Finally, the QDs 
were re-dissolved in distilled water. 
3.2.3 Preparation of gelatin NPs 
Gelatin NPs were made by a two-step desolvation approach with slight modification.28 
Briefly, 1.25g of gelatin type A powder was dissolved in 25 mL nanopure water under 
constant heating at 40 oC. In order to achieve the desolvation of gelatin, 25 mL of acetone 
was then added rapidly to this solution. The supernatant was discarded and the remaining 
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high molecular weight (HMW) gelatin was re-dissolved by adding another 25 mL of 
nanopure water at 40 oC. The pH of this solution was adjusted to 2.5. The gelatin was 
then desolvated again by dropwise addition of 75 mL acetone during 15 min under this 
constant heating. A white milk-like solution appears when 55 to 60 mL of acetone was 
introduced into the mixture. After 10 min of stirring, 0.5 mL of 25% glutaraldehyde 
solution (Sigma-Aldrich) was added to crosslink the particles. After another 30 min of 
stirring, the dispersion was centrifuged at 6500 rpm for 10 min. The particles were 
purified by repeating re-dispersion with acetone (30%) and centrifugation. After the final 
centrifugation, the particles were freezing-dried overnight and kept at 4 oC for further 
studies. 
3.2.4 Preparation of QDs-GNP1 by direct encapsulation of QDs in 
GNPs. 
Figure 3.1 is a schematic illustration of the preparation of QDs-GNP1. Briefly, 1.25 g of 
the gelatin powder was first dissolved in water (25 mL) and acetone (25 mL) at 40 oC, 
followed by centrifugation. The extracted gelatin was then re-dissolved in 40 mL of an 
acidic water solution (pH 2.5). Hydrophilic MUA-QDs (1.0 mL; 0.25 mg/mL) were 
added to the gelatin mixture at this point. Acetone was added (drop wise) to the solution 
to form NPs. After 30 min of stirring, 0.5 mL of glutaraldehyde solution (25% v/v) was 
added as a cross-linker to stabilize the NPs. The particles were then purified and washed 
using an ethanol and acetone mixture, and freeze-dried overnight. 
 
Figure 3.1 Schematic illustration of preparation of QD-GNP1 
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3.2.5 Preparation of QDs-GNP2 
Figure 3.2 shows the scheme of preparation of multilayer QDs-GNP2 by LBL deposition 
method. LBL coating process starts from coating of two stabilized bi-layer of PSS and 
PDAC at pH 6.0. In brief, a supporting film consisting of two PE bilayers by the alternate 
adsorption of PSS solution (0.3 mg/mL in nanopure water, pH 6.0) and PDAC (0.3 
mg/mL in nanopure water, pH 6.0) twice first covered the surface of as-prepared GNPs 
(~200 mg). The polyanion PSS was deposited as the first layer on the positive GNPs. 
After formation of two supporting bilayers, MUA-QDs (0.5 mg/mL in nanopure water, 
pH 9.0) were deposited toward the PDAC layer, followed by the cycle of 
PSS/PDAC/MUA-QDs adsorption. For adsorption of each layer, the suspending was 
allowed for 15 min under vigorous shaking. Followed that, the particles were washed 
with nanopure water and collected through centrifugation (5000 g for 5 min). The cycle 
was run repeatedly until the formation of four layers of MUA-QDs on the GNPs. After 
adsorption of the final MUA-QDs layer, the particles were protected by depositing a layer 
of PSS. The multilayer NPs were then purified, freeze-dried and stored at 4 oC ready for 
use. 
 
Figure 3.2. Schematic illustration of preparation of QDs-GNPs by LBL technique. 
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3.2.6 Characterization 
Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) 
coupled with energy-dispersive X-ray spectroscope (EDX) were used to analyze the 
morphology and composition of all the NPs. The TEM images were obtained using a 
Philips CM-10 microscopy operating at 100 kV. A high resolution TEM (HRTEM, JEOL 
2010 F, operating at 200 kV) was used to analyze the crystalline structure of MUA-QDs. 
The SEM analysis was taken by a Hitachi 3400s SEM coupled with EDX. The average 
diameter of the multiple layer NPs was calculated from TEM images by analyzing at least 
200 NPs for each sample using ImageJ software (National Institutes of Health, USA).  
The Zeta (ζ) potentials of the GNs with and without LBL coatings were measured by 
Malvern Zetasizer 3000HSA, and calculated as the mean of five individual 
measurements. The functional groups of nanomaterials were studied by using Fourier 
transform infrared (FTIR) spectrophotometer (Bruker FTIR-IFS 55, Germany). UV-
visible absorption spectra were recorded by UV-3600 spectrophotometer (Shimadzu, 
Japan). PL spectra and quantum yields were measured by a QuantaMaster™ 40 
Spectrofluorometer (Photon Technology International Inc., London, ON). 
3.2.7 Analysis of pH effect in photostability 
The pH effect on the PL stability of MUA-QDs and QDs-GNP2 were investigated further 
under the excitation wavelength (λex) at 470 nm. Corresponding amounts of MUA-QDs 
and QDs-GNs were suspended in distilled water with different pH values, i.e., 1, 4, 7, and 
9, respectively. The pH value of the aqueous media was adjusted by using HCl and 
NaOH. Each measurement was repeated at least three times.The light source is a pulsed 
dye laser pumped by a pulsed nitrogen laser with the dye wavelength set at 480 nm (the 
bandwidth of the dye laser output is about 0.04 nm). The emission was measured with a 
monochromator set at 620 nm. Furthermore, there was a 550 nm long-pass filter used on 
the emission side so that no excitation light can enter the detector, that is, the scattering 
effect is ruled out. The PTI-patterned Strobe technique measures fluorescence decay 
curves (i.e., fluorescence intensity as a function of time) directly. It is considered a faster 
measurement than TCSPC (Time-Correlation Single Photon Counting) by using a 
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nonlinear detection time scale to record the fluorescence intensity. The data analysis was 
performed with Felix GX analytical software package using a 1-to-4 exponential fitting 
function by χ2 minimization employing Marquardt−Levenberg  algorithm with iterative 
reconvolution. In order to carry our reconvolution, an instrument response function (IRF) 
was measured by using a scattering suspension of Ludox in deionized water. The PL 
decays required either a single or double-exponential function to fulfill fitting criteria, 
such as the value and the randomness of residuals. For double exponential decays the 
intensity-weighed average lifetimes were calculated using the following equation 
(Equation 3.1) ,40 
τave = ∑ aiτi2/∑ aiτi                                   (Equation 3.1) 
where 𝑎𝑖 are the pre-exponential weights and 𝜏𝑖 the decay times obtained in the multi-
exponential fitting. 
3.2.8 Cell viability/cytotoxicity study 
The toxic effects of nanomaterials studied in this chapter on NIH/3T3 mouse cells 
(ATCC) was tested by a commercial kit (MultiTox-Fluor cytotoxicity assay). The assay 
was done following the manufacturer’s instruction. Briefly, 10,000 cells per well (of 96-
well) of the 3T3 cells were cultured in DMEM medium supplemented with 10% FBS at 
37 °C, 5% CO2. After 24 hrs of culture, the medium was replaced with fresh medium 
containing 5-fold serial diluted QDs-GNPs and MUA-QDs ranging from 25 mg/mL to 
0.2 mg/mL, and from 6.25 mg/mL to 0.05 mg/mL, respectively. Cells without any 
treatment were used as controls. After another 24 hrs, 20 μL of 2 X MultiTox-Fluor 
multiplex cytotoxicity assay reagent was added to each well. An Omega microplate 
reader (BMG Labtech, Ortenberg, Germany) at an excitation of 400 nm and an emission 
of 505 nm was used in this study. 
3.2.9 In vitro fluorescence imaging   
NIH/3T3 mouse fibroblast cells (2 x 105 per petridish, glass bottom petridishes), were 
cultured in DMEM medium supplemented with 10 % FBS at 37 °C, 5 % CO2, for 24 hrs. 
The cells were then rinsed by PBS, and subsequently treated with DMEM mediums 
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spiked with 0.1 mg/mL MUA-QDs, QDs-GNP2 and GNPs, respectively, and incubated 
for 24 hrs. The treated cells were washed by PBS for three times and fixed using a PBS 
solution containing 2.5% glutaraldehyde under for 30 min under mild shaking. After that, 
the cells were washed for another three times by PBS and incubated with a PBS 
mounting solution containing DAPI solution for 30 min. Afterwards the cells were 
washed with PBS for another five times and were examined by a LSM Zeiss 510 Duo 
Confocal microscopy.  
3.3 Results and Discussion (I)  
 The initial work using QDs-GNP1 are presented and discussed in this section. 
3.3.1 Characterization  
The diameter of the MUA-QDs is estimated to be 5 ± 1 nm by TEM and HRTEM, as 
shown in Figure 3.3a. The well-resolved lattice fringes on the HRTEM micrographs are 
typical crystalline structures of CdSe QDs. Figure 3.3b shows spherical QDs-GNP1 with 
average diameters of 150 ± 10 nm. In addition, TEM shows that free MUA-QDs are 
generally not found outside GNPs.  
 
Figure 3.3 TEM micrograph of MUA-CdSe QDs (a) and (b) QD-GNP1. 
FTIR was then carried out to investigate the encapsulation of MUA-QDs in GNPs. Figure 
3.4 shows FTIR spectra of MUA-QDs, GNPs and QDs-GNP1. C =O stretching can be 
found in both GNPs and MUA occurring at ~1660 cm-1. GNPs in the FTIR spectrum 
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show -NH bending between 1550 cm-1 and 1500 cm-1. Peaks at 1660 cm-1 are assigned to 
the imide C–N group formed via a cross-linking reaction between gelatin and 
glutaraldehyde, which is close to -C =O stretching. For MUA-QDs, previous studies have 
shown that the carboxyl group of MUA may participate in the hydrogen-bonding 
processes. The absorption band at 1200 cm-1 is attributed to the C–OH stretching of 
MUA. The band at 1430 cm-1 can be found in both and is assigned to a combination of 
the symmetric COO- stretching band of the carboxylate anion and the -CH2 scissors 
deformation of the carboxylic acid.41 Unfortunately, they are quite weak, and could not 
be identified in QDs-GNP1. Also, most of characteristic peaks of MUA-QDs (stretches of 
–C=O, –CH2 and –OH groups) are observable in GNPs.  
 
 
Figure 3.4 FTIR spectra of MUA-QDs, GNPs and QD-GNP1 
A fluorospectrometer was then used to study the encapsulation of MUA-QDs in GNPs 
(Figure 3.5). The maximum fluorescent emission peak (λem max) is found at 630 nm for 
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MUA-QDs under an excitation wavelength (λex) of 460 nm. As expected, there is no 
emission from the plain GNPs. There is a 24-nm red-shift in λem max while MUA-QDs 
were encapsulated into GNPs. Previous reports indicate a blue-shift of λem max for the 
gelatin encapsulating PbS QDs, which was claimed to be due to the polar environment of 
gelatin on the dipole interaction of PbS QDs.24 However, it should be mentioned that the 
PbS QDs used previously were synthesized by a hydrothermal method without the 
protection of a stabilizer. In the other words, the surface of PbS QDs would be very 
sensitive to environmental conditions. In our case, CdSe QDs were capped by long-chain 
MUA molecules, which protect the surface atoms of QDs from direct interaction with 
solution. The red-shift at the emission wavelength might be caused by extension of the 
exciton wavefunction of CdSe QDs to the outer organic ligands. This results in a decrease 
in the confinement energy of the exciton and the wavelength red-shift.39 
 
Figure 3.5 Fluorescent spectra of MUA-QDs, GNPs and QD-GNP1 
The QDs-GNP1 was further studied by using confocal laser scanning microscopy (Figure 
3.6). The inset shows agglomerated NPs under the bright field. When the excitation, λex, 
was 460 nm, a bright photoluminescenct signal could be captured from the NPs (green 
dots in Figure 3.6). This further demonstrates that MUA-QDs can be successfully loaded 
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into GNPs. No free MUA-QDs after the encapsulation are identified by confocal laser 
scanning microscopy. It is noted that the isoelectric point (PI) for MUA is ~ 6, and the 
acid pH (2.5) in the second desolvation may cause protonization of MUA-QDs, resulting 
in slight aggregation. As shown in Figure 3.6, the photoluminescence was well 
distributed around those QDs-GNP1; it seems that the possible slight aggregation did not 
affect the homogenous encapsulation process. In addition, ~ 1 g of QDs-GNP1 could be 
produced in each process. The amount of QDs incorporated inside of NPs can be 
adjustable. 
 
 
Figure 3.6 Confocal fluorescent of microscopy images of QD-GNP1. BF indicates 
bright field and DF indicates the dark field, respectively. 
3.3.2 Cytotoxicity 
The cytotoxicity effects of the GNPs, CdSe QDs and QDs-GNP1 were studied using 
NIH/3T3 mouse fibroblast cells. Cells were cultured to confluence. Different samples 
were mixed with cells in medium and were continually cultured for 24 h. Figure 3.7 
shows that MUA-QDs not encapsulated in GNPs have a significant adverse effect on cell 
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viability when the concentration of MUA-QDs increases from 0.01 to 0.05 mg/mL. 
Whereas GNPs and QDs-GNP1, at concentrations up to 5 mg/mL, are not toxic to cells. 
In addition, no QDs released from GNPs have been found over a period of 5 days. 
In sum, we initially used nature polymer gelatin as coating material for QDs to produce 
luminescent NPs. The luminescent NPs, i.e. QDs-GNP1, exhibit good biocompatibility. 
However, as we discussed above, the optimum pH ranges (2.5-4) for formation of GNPs 
can cause aggregation of MUA-QDs, and may result in photobleaching. Further 
improvement in photostability of gelatin-QDs system is required for its use in 
bioimaging.  
 
 
Figure 3.7 Cytotoxicity analysis of GNPs, MUA-QDs and QD-GNP1. 
3.4 Results and Discussion (II) 
This section presents the results for preparation of a new type of gelatin-QDs hybrid NPs 
system (i.e. QDs-GNP2) with bight luminescence, good photostability and 
biocompatibility for potential cell imaging use. 
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3.4.1 Materials characterization  
The average diameter of the core-shell QDs-GNP2 is estimated at 484 ± 40 nm through 
SEM and TEM results (Figure 3.8 a). TEM micrograph (Figure 3.8 b) clearly shows the 
multiple layers of dense dark dots on the shell, which are attributed to the assembled 
CdSe QDs verified by a high-resolution TEM. Element analysis carried by EDX (Figure 
3.8 c) indicates the existing of elements S, Cd and Se on the layers, which are attributed 
to the capping molecule MUA and two main compositions of the QDs.  
The ζ potential of GNPs, MUA-QDs, and QDs-GNP2 are 24.1± 0.4 mV. −29.9 ± 0.48 
mV, and −16 ± 0.4 mV, respectively.  The surface of the core−shell QDs -GNP2 is 
negatively charged. Two specific bands located at 1020 cm-1 and 1130 cm-1 are found in 
the FTIR spectra (Figure 3.9), which are assigned to the PSS characterization stretches 
(Figure 3.9 b). The results indicate that the MUA-QDs have been successfully assembled 
onto the GNPs with the assistance of PE layers. In addition, it is estimated that there are 
0.25 mg QDs per 1 mg core-shell QDs-GNP2 (1:4 w/w) by comparing with the PL 
intensities of QDs and QDs-GNP2 as mentioned in experimental section (Figure A1, see 
appendix 1). 
 
Figure 3.8. Characterization of QDs-GNP2 by electron microscopy. 
(a) (b)
(c)
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Figure 3.9. FTIR spectra of (i) bare GNPs, (ii) PE coating GNPs, (iii) single layer QDs 
coating GNPs,(iv) multilayer QDs coating GNPs, and (v) free MUA-QDs. 
3.4.2 Absorbance and PL spectra 
Figure 3.10 displays the absorbance and PL emission spectra of MUA-QDs and QDs-
GNP2, respectively. It indicates that the first exciton absorption peak (λab) of MUA-QDs 
is around 600 nm, and the maximum PL is occurred with the emission wavelength (λem) 
at 617 nm. It is noted that a very slight blue shift (3 ± 1 nm) occurs to both λab and λem of 
QDs-GNP2 as comparing to those of MUA-QDs. PL emission of small semiconductor 
QDs are known to be dependent on either band-to-band recombination in the nanocrystal 
core 30, 42 or radiative surface states.31-33 In our study, the blue-shift could be attributed to 
the latter mechanism because PE matrix assisting the assembly of MUA-QDs layers may 
offer a  higher degree of surface passivation of charges via interacting with surface atoms 
of QDs.31 Our results also indicate that the relative quantum yield (QY) of QDs-GNP2 is 
1.8-fold higher than that of the free MUA-QDs. Thus, PE matrix may minimize the 
surface nonradiative recombination and increase confinement of charge carrier, which 
consequently cause higher band-gap energy, shorter wavelengths and higher quantum 
yields (QY).31, 32 
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Figure 3.10.  (a) Absorbance and (b) PL spectra for MUA-QDs and corresponding QDs-
GNP2. 
3.4.3 The pH effects on photostability 
The photoquenching of luminescence at low pH value limits the application of QDs in 
bio-imaging in vitro and in vivo,37, 42 for some important physiological cells normally live 
in low pH values (<7), including endosomes and lysosomes inside cells (pH 5-6.5) and 
some tumor cells (pH 6-6.9).43, 44 Here, we further studied the proton-resistant capability 
of QDs-GNP2 in different pH values with the comparison of MUA-QDs. The weight 
ratio of MUA-QDs to QDs-GNP2 is 1:4 to maintain the same amount of QDs in both 
samples. Figure 3.11a shows that the PL intensity of MUA-QDs decreases with 
decreasing of pH value from 9 to 1, whereas the PL intensity of QDs-GNP2 is relatively 
stable, independent- pH value. It shows that the PL intensity of QDs-GNP2 is two times 
higher than that of MUA-QDs at pH 1.0. The decreasing behavior of PL intensity could 
result from the aggregation of free MUA-QDs at low pH, which could be caused by the 
protonation of capping material MUA molecule. Agglomerations were observed in low 
pH levels (data not shown). 
 In addition, the average lifetime (τave) of MUA-QDs and QDs-GNP2 as a function of pH 
value (pH at 1, 4, 7, and 9) were measured using the TM-30 Laser Strobe time-resolved 
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fluorometer, as shown in the Figure A1 (see appendix), in which the experimental data 
are shown as dots, and numerical fits as lines. 
As per equation 3.1, the calculated average lifetime (τave) of QDs-GNP2 is about 889 ± 
23 ps, which is 3-fold longer than that of MUA-QDs (263 ± 10 ps) at pH 7.0. It is noted 
that most reported lifetime for CdSe QDs is 3 to 20 ns. Our short calculated average 
lifetimes of produced QDs could be related to the defects of the produced QDs caused by 
oxidation. The PL decay of MUA-QDs is pH- dependent as shown in Figure 3.11b, 
which is in agreement with previous reports.45 The average lifetime (τave) for free MUA-
QDs decreases dramatically from 285 ps to 112 ps with decreasing pH value from 9.0 to 
1.0. In contrast, the τave of QDs-GNP2 (775 ps ~ 914 ps) does not change significantly 
along with the change of pH value from 9 to 1. Acid etching results in the changes of 
nanocrystal semiconductive structures, and lead to the decreases of the PL intensity and 
lifetime of QDs.31 
Here, the negatively changed PSS layer may neutralize the surrounding protons in acidic 
conditions, and, therefore, against the potential proton effect on the PL photostability of 
the core-shell QDs-GNP2. In addition, the immobilization of QDs on GNP2 prevents 
QDs with negative changes from aggregations caused by the addition of protons. As a 
result, the PL signals of QDs-GNP2 are relatively stable in a broad range of pH value 
from 9 to 1.  
 
Figure 3.11.  The pH effects on (a) PL intensity and (b) average lifetimes  
 
 
65 
 
3.4.4 Cytotoxicity analysis of QDs-GNP2 
We further investigated the cytotoxicity of the QDs-GNP2 with the comparison of MUA-
QDs. NIH/3T3 mouse fibroblast cell line was treated by free MUA-QDs and QDs-GNP2 
with weight ratio of 1 to 4 to maintain the same amount of QDs in both samples. 
MultiTox-Fluor assay was used to analyze the cell viability. When the concentration of 
QDs-GNP2 increases from 5 mg/mL to 0.2 mg/mL, the relative cell viability (%) 
increases up to 140% as compared to the control samples (Figure 3.12). It is noted that 
GNPs may enhance the cell proliferation.46 As indicated by above result (Figure 3.6), no 
significant toxic effect was imposed on cells when the concentration of GNP2 is up to 5 
mg/mL. Whereas the relative cell viability (%) decreases from 100% to 82% when the 
concentration of MUA-QDs increases from 0.05 mg/mL to 1.25 mg/mL. With further 
increasing concentration of MUA-QDs up to 6.25 mg/mL, the cell viability dramatically 
decreases to 20%. Meanwhile, the relative cell viability percentage dramatically drops to 
50% when the concentration of QDs-GNP2 increases up to 25 mg/mL, which might be 
related to the negative interference of florescent detection caused by the high 
concentration of non-transparent QDs-GNP2. 
 
Figure 3.12. Cytotoxicity profile of MUA-QDs and corresponding QDs-GNP2 after 24 
hrs incubation with 3T3 cells. Percent viability is expressed relative to control cells (n=3) 
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3.4.5 In vitro bio-imaging application 
We subsequently investigated the core shell QDs-GNP2 in vitro bio-imaging applications 
by using confocal microscopy. The NIH/3T3 mouse fibroblast cell line was applied and 
incubated with 0.1 mg/mL MUA-QDs and 0.4 mg/mL QDs-GNP2 for 24 hrs, 
respectively. Figure 3.13a indicates that the cells are alive with mixing GNPs (0.3 
mg/mL). As shown in Figure 3.13b, MUA-QDs are observed on the surface of most of 
cells (red color), which is in agreement with previous reports.8 Very few MUA-QDs are 
suspended in the culture media. The nonspecific cellular uptake of MUA-QDs results 
from passive endocytosis due to its very small particle size.8, 47-49 In addition, the 
produced QDs-GNP2 with high photostability (red color) are preferred to attach on the 
surface of the cells (Figure 3.13c). It is unlikely that NIH/3T3 mouse fibroblast cells 
could naturally uptake of large QDs-GNP2 with average diameter of 480 ± 40 nm. The 
internalization of NPs with such a large diameter through passive endocytosis could 
merely be possible to specialized mammalian cells (such as monocytes, macrophages and 
neutrophils) via phagocytosis.50 Previous reports indicate that the negatively charged 
surfaces (PSS dominated) are favorable to cell adhesion and spreading.51 In addition, the 
advantage of using PSS as an out layer may lead to longer circulation time in vivo. 52 
 
Figure 3.13  Confocal microscopy images of (a) GNPs (0.3 mg/mL), (b) MUA-QDs (0.1 
mg/mL), and (c) QDs-GNP2 (0.4 mg/mL) after co-incubation with NIH/3T3 mouse 
fibroblast cells. All nucleuses were labeled with DAPI (blue). 
Consequently, our biocompatible and fluorescent QDs-GNP2 are favorable to attach onto 
the cell surface, and can be used as an alternative fluorescent imaging agent for cell 
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labeling, especially in acidic conditions. It is also noted that the QDs-GNP2 interact with 
cells through the electrostatic interaction (nonspecific interaction). Further efforts will be 
taken to modify the surface of the hybrid nanospheres for targeted cell 
3.5 Conclusions and Prospects  
In conclusion, we have prepared two different biocompatible quantum dots-GNPs 
systems (QD-GNPs) for bioimaging application. The first system involves utilizing 
gelatin for directly embedding quantum dots (QD-GNP1) to form a quantum 
dots/gelatine core/shell structure. TEM result show QD-GNP1 has an average diameter of 
200 nm with QD embedded. QD-GNP1 exhibits bright fluorescence with maximum 
emission wavelength at 613 nm. The results from cytotoxicity test indicate good 
biocompatibility of QD-GNP1. To improve photostability of QD-GNPs system, we 
further prepared a new system consist of a QDs embedded polyelectrolytes (PE) shell 
coated gelatin nanoparticles (QD-GNP2) through a LBL process. Electronic microscopy 
results show the QD-GNP2 has a gelatin core and PE shell, with an averaged diameter of 
~480 nm. Four layers of CdSe QDs were showed embedded in the PE shell. The 
nanocomposites exhibit good dispersibility and extremely bright and stable PL property 
in aqueous solution under a wide pH range. The quantum yield and lifetime of 
encapsulated QDs are found improved due to the multilayer PE protection. Good 
biocompatibility of the as-prepared NPs is further demonstrated by cytotoxicity study. 
The bright PL allows the NPs for detecting and labeling living 3T3 cells, which indicates 
the QDs-GNPs system could be a suitable candidate for bio-imaging application. We 
believe that our QDs-GNPs systems could be used for in situ real-time 
monitoring/imaging drug delivery in future. 
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4.1 Introduction 
Bacteria can lead to serious infectious diseases and environmental contamination, and 
bring a huge public health burden.1 In particular, gram-negative bacterium Escherichia 
coli and gram-positive bacterium Staphylococcus aureus are known as two of the leading 
causes in food borne diseases in the world.2, 3 In addition, bacterial infections are also 
found in the skin, soft-tissue, bone, joint, and endovascular disorders.4, 5 Antibiotics have 
been developed to treat bacterial infections, but the effective dosage is not well 
controlled. In addition, the unique cell wall made of highly cross-linked peptidoglycan 
offer a rigid shell to protect the gram-positive bacteria from osmotic pressure, external 
hazard macromolecules permeability and antibacterial enzyme digesting, which make the 
treatment of their infections with much difficulty.6 Laboratory diagnosis of bacterial 
infectious disease depends mainly on techniques such as cell culture, enzyme-linked 
immunosorbent assay (ELISA) and polymerase chain reaction (PCR) , while they are 
normally time-consuming and involved with multiple steps that affect the assay 
efficiency.7, 8 In addition, very few bacterial cells may cause disease as they can double 
their population less than 20 min.9 Therefore, rapid capture, detection, and 
decontamination of bacteria are strongly demanded to avoid or minimize contamination 
of the environment, food, and infections. 
In recent, engineered magnetic nanoparticles (MNPs) conjugated with biomolecules have 
shown promises in applications in drug delivery, magnetic separation,10, 11 sensor, cell-
tracking,12 and bio-imaging,13, 14 because of their inducible magnetization, tunable size, 
nontoxic and biodegradable. Bio-molecules, such as antibody,15 antibiotics,16-19 
carbohydrate,20 and small organic molecules,21 have been reported to conjugate MNPs for 
bacterial labelling and detection. In particular, bio-conjugated antibiotics to nanostructure 
can offer a novel manner to simultaneously separate and kill the bacteria from 
contaminated source at the early stage. For example, Xu and co-workers conjugated FePt-
based magnetic NPs with vancomycin, and through peptide binding captured E. coli at a 
low concentration of 3 x 104 cells/mL.16, 17, 19 El-Boubbou et. al. conjugated lectin to 
MNPs and used mannose to bind, capture and kill.E. coli 20 
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To improve the efficiency and versatility of nanoparticles (NPs) in numerous 
applications, multiple functionalities have been incorporated to form hybrid MNPs. In 
particular, optical properties such as fluorescence allow sensitive and quantitative 
detection of bacteria 22 and visualization of cell structure.23 Thereby, it is of advantage to 
develop of fluorescent magnetic nanoparticles (FMNPs) that posse both fluorescent and 
magnetic properties, regard to detection, imaging and cell tracking. Typically, FMNPs 
include a core–shell structure, i.e. a magnetic core coated with a fluorescent shell. The 
fluorescent shell can be composed of polymers and inorganic materials loaded with 
organic dye,24-26 quantum dots,27 or other complexes.28, 29 Silica is one of the well-studied 
materials that can act as a shell due to its functional surface, and its unique porous 
nature.30-32 Previous studies demonstrated that fluorophore-loaded mesoporous SiO2 NPs 
are 20 times brighter than semiconductor quantum dots.33, 34 They can be taken up by 
dendritic cells for cell tracking and cancer treatment.35, 36 The magnetic cores of most 
FMNPs are intended to be Fe2O3-rich materials.37 However, compared to hematite 
(Fe2O3) and other magnetic materials, magnetite (Fe3O4) shows higher magnetization, 
about 65 emu/g 32, 38 and has various applications in biosensing and imaging.39, 40 
The common method for preparation of silica coated iron oxide nanoparticles (SMNPs) 
involves two steps, i.e. synthesis of iron oxide nanoparticles (IONPs) and post coating of 
silica on the surface. Several methods have been developed to synthesize IONPs, 
including co-precipitation, hydrothermal and thermal decomposition method. Co-
precipitation process is one of the most preferred ways to produce magnetite and 
maghemite, which involves co-precipitation of Fe2+ and Fe3+ in aqueous solution by 
addition of base. The reaction runs under mild condition (room temperature) and the 
products are hydrophilic and ready for further silanation. However, the drawbacks are 
poor crystalline of the particles and difficulty in controlling of the size distribution. The 
other two approaches, in particular thermal decomposition method, require high 
temperature and thus can produce particles in good crystalline structure and narrow size 
distribution. However, the NPs are usually coated by hydrophobic ligands for thermal 
decomposition method. Thus additional surface modification such as ligand exchange to 
bring NPs into aqueous solution is required prior for further coating with silica shell. For 
silica coating, there are two widely used methods. The first one is based on the Stöber 
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process,41 which comprises the hydrolysis and condensation of a sol-gel precursor such as 
TEOS. In the second method, silica shell is produced via the microemulsion process, 
where reverse micelles are use to confine and control the condensation of TEOS.42 In 
both methods, fluorescent dyes can be conjugated to silane (such as APTS) before 
condensation of TEOS, to form fluorescent shell.  
Alternative strategy for preparation of FMNPs is one-pot synthesis scheme. In our group, 
we previous developed a one-pot synthesis to produce dye labeling silica-coated 
magnetite NPs. The process simplifies the reaction by co-precipitation of iron salt 
directly in an oil-water micelle, followed by condensation of TEOS on the IONPs surface 
in the same solution. Improved fluorescent properties and magnetic properties have been 
reported.  
In this chapter, we reported preparation of a new bioconjugation of FMNPs with 
antibiotic gentamicin for ubiquitous capture, detection and decontamination of bacteria 
applications. We introduced and compared two approaches in preparation the FMNPs, 
i.e. one-pot co-precipitation way and two-step decomposition method. The as-made NPs 
are thus named FMNP1 and FMNP2, respectively. In addition, gentamicin (Gm) is a 
FDA approved thermal-resistant antibiotic for the treatment of infection caused by gram-
negative bacteria and susceptible gram-positive bacteria. The amino groups of Gm show 
positive charges through protonation in physiologic solutions, which contribute to the 
interaction of Gm with lipopolysaccharides (LPS) on the surface of Gram-negative 
bacteria and phospholipids and teichoic acid on the surface of Gram-positive bacteria, 
respectively.43, 44 We thoroughly investigate the interaction between bacteria and FMNPs 
with/without Gm-bioconjugation. Meanwhile, the detection sensitivity and toxic effect 
are also investigated. 
4.2 Experimental 
Unless otherwise stated, chemicals were obtained from Sigma-Aldrich. 
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The scheme in Figure 4.1 illustrates the preparation and bio-conjugation of FMNPs for 
bacterial capture. The experimental details are described below.  
 
Figure 4.1 Schematic illustration of the synthesis of FMNPs used for E. coli capture and 
magnetic separation in solution 
4.2.1 Preparation of FMNP1 by one-pot method 
The FMNP1 were produced by an one-pot reaction involving a process of base-catalyzed 
precipitation of Fe2+/Fe3+, followed by the condensation of tetraethylorthosilicate (TEOS, 
99%), and the in situ encapsulation of fluorescein isothiocyanate (FITC, 90%) in the shell 
as shown in Figure 4.1. Briefly, 7.3 g of cetyl-trimethylammonium bromide (CTAB) 
(98%) was added to 100 mL of toluene (99.8%). The mixture was stirred at 600 rpm for 4 
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h, followed by the slow addition of an aqueous solution of FeCl2/FeCl3 (0.22 g/0.56 g, 7.3 
mL; FeCl2, 98%, FeCl3, 97%). The mixture (solution A) was stirred vigorously for 8 h. 
Then, 1 mL NH4OH solution (28%) was added drop-wise to the solution. Solution A was 
stirred for another 4 h. Meanwhile, 5.5 mg fluorescein isothiocyanate (FITC) and 25 µL 
aminopropyltriethoxysilane (APTS, 98%) were mixed to form N-1-(3-
triethoxysilylpropyl)-N’-fluoresceyl thiourea (FITC-APTS). After 2 h, 2.5 mL of TEOS 
was added to the FITC-APTS solution. This mixture (solution B) was stirred 
continuously for an additional 3 h using aluminum foil to protect the dye conjugate from 
light. Solution B was then added drop-wise to the main reaction of the solution A pot and 
continuously stirred for 5 days. All reactions were kept under N2 atmosphere. Aluminum 
foil was used to cover the reactor to protect the products from photo-degradation. Finally, 
the reaction was stopped by addition of 20 mL ethanol. The particles were washed with a 
mixture of ethanol/acetone (1:1, v/v) and purified by repeat centrifugation. The as-made 
FMNP1 were then freeze-dried and stored in the dark.  
4.2.2 Preparation of FMNP2 by two-step coating method 
The FMNP2 were prepared by a two-step process. Firstly, monodisperse IONPs were 
synthesized through a modified thermal decomposition method.45 In brief, 1.32 g of 
FeCl3 and 7.4 g of sodium oleate (TCI, 95%) were dissolved in a mixture of 16.3 mL of 
absolute ethanol, 13.08 mL of water and 28.5 mL of hexane (95%). The solution was 
refluxed at 60 ºC for 4 h, followed by washing with a solution of ethanol and water (1:1, 
v/v) five times. The resultant iron-oleate precursor was then dried under vacuum 
overnight at 70 °C. Afterwards, 1 g of wax-like precursor was re-dissolved in a solution 
of 177.3 μL oleic acid (99%) and 7.1 mL triethylamine (98%). The solution was stirred 
vigorously and heated to 360 °C rapidly under argon atmosphere, and then aged for 1 h. 
After that the solution was cooled down, washed with hexane and ethanol (1:3, v/v) 
mixture and purified by centrifugation for three times. The particles were finally 
dissolved in chloroform and kept at room temperature. 
Silica coating of IONPs were carried out through a modified sol-gel method.46 Firstly, 1 
mg of fluorescein isothiocyanate was dissolved in 0.5 mL of absolute ethanol, followed 
by addition of 10 µL of APTS. The solution was stirred for 2 h. In another vessel, 50 mg 
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of IONPs were mixed in 20 ml of an aqueous solution of 2% CTAB. The mixture was 
stirred vigorously and heated to 70 °C to boil off chloroform. The NPs mixture was 
further filtered through a 0.45 μm syringe filter to remove large aggregates. Next, 5 mL 
of the filtered mixture was added into a solution of 43 mL water and 350 μL NaOH (2 M) 
and heated to 70°C. The mixture of 0.5 mL of TEOS and 10 μL of APTES-FITC solution 
was then slowly added to the CTAB aqueous solution. After 15 min, 127 μL of 
trihydroxysilylpropylmethylphosphonate (THPMP) (42%) was added to the solution and 
stirred for another 2 h under dark. Then, the as-synthesized FMNP2 were precipitated by 
adding excess methanol and collected by centrifugation. To remove CTAB, the FMNP2 
were further re-dispersed and heated at 60 °C for 15 min in a solution containing 160 mg 
NH4NO3 and 60 mL 95% ethanol. Afterwards, the NPs were purified by by repeating 
centrifugation and washing with ethanol. Finally, the FMNP2 were freeze-dried overnight 
and kept under dark ready for use. 
4.2.3 Bioconjugation of FMNPs with Gm 
For bioconjugation of Gm, both FMNP1 and FMNP2 at 2.5 mg/mL in water were reacted 
with a glutaraldehyde solution (Glu, Grade I, a final concentration of 3% in water) 
overnight in the dark, respectively. The mixture was then purified by centrifugation (5800 
rpm for 5 min) to remove the supernatant, and further re-suspended in water. The 
purification process was repeated twice, and the Glu conjugated FMNPs were then 
freeze-dried. To immobilize Gm onto the surface of the FMNPs, a solution containing 
gentamicin sulfate (1 mg/mL) and 2.5 mg/mL FMNPs was mixed and stirred overnight 
under dark. The unbound Gm was removed by repeated centrifugation and washing, as 
described above. The solution was then mixed with 1% bovine serum albumin (BSA, 
96%) solution for 1 h to block free formyl group onto the surface of the FMNPs. Finally, 
the purified Gm-FMNPs were freeze-dried and stored in the dark at 4 °C. In addition to 
the negative control samples of bare FMNPs and Glu-FMNPs, another negative control 
sample used to evaluate the Gm-bioconjugation was ethanolamine (EA, 98%). The 
conjugation of EA to FMNPs followed with the same procedure described above.  
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4.2.4 Characterization 
The morphology of NPs and their interaction with bacteria was examined by TEM and 
TEM-energy dispersive X-ray spectrometry (TEM/EDX). The TEM images were 
obtained using a Philips CM-10 microscope operating at 80 kV. The magnetic properties 
of both IONPs and MNPs were measured by Vibrating Sample Magnetometer 7404 
(VSM, Lakeshore Inc.). The hysteresis loop was measured at room temperature under 1 
kOe (1 T). A superconducting quantum interference device (SQUID, Quantum Design) 
was used for measuring of blocking temperature of FMNPs. The zero-field-cooled (ZFC) 
and field-cooled (FC) magnetization curves of the FMNPs were recorded at 50 Oe over a 
temperature range of 5 to 300 K. The sample capsule was diamagnetic and did not 
contribute to the measured result.  
The Fe K-edge X-ray absorption near edge structure spectroscopy (XANES) study was 
conducted to investigate the composition of NPs by using the Soft X-ray 
Microcharacterization Beamline (SXRMB) at the Canadian Light Source (CLS). The 
specimens were placed on the sample manipulator in a vacuum chamber (~10-8 Torr). 
XANES were collected in Total Electron Yield (TEY) by measuring the specimen current 
in the presence of a voltage bias. In addition, the XANES spectra have been normalized 
to I0, the intensity of the incoming photon beam.  
Fluorescence microscopy (Zeiss Axio Imager Z1) analysis was conducted to study the 
interaction between the bacterial cells and FMNP1 with and without Gm bioconjugation 
by placing glass slides of the samples under an excitation wavelength (λex) of 492 nm. In 
addition, the fluorescent emission signals of the FMNP1 were detected by 
fluorophotometry (QuantaMsterTM 30, PTI) with an excitation wavelength (λex) of 492 
nm. Fourier transform infrared (FTIR) transmittance spectrometry was carried out to 
identify the Gm bioconjugation. A Bruker Vector 22 was used in the range of 600–4500 
cm-1 with a resolution of 4 cm-1 and 64 scans. 
4.2.5 Bacteria Capture  
In a typical experiment, bacteria E. coli (K-12, sub-strain W3110) and S. aureus (ATCC 
33807) were grown at 37 °C for 24 h in broth media, respectively. The optical density 
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(O.D.) of this culture was adjusted to having a concentration of approximately 1 x 107 
CFU/mL. The cells were harvested by centrifugation (8000 rpm, 5 min) and further re-
suspended in phosphate buffered saline (PBS, 0.01 M, pH 7.4) buffer containing Gm-
FMNPs (final concentration of 0.1 mg/mL). The mixtures were further incubated for 20 
and 60 min, respectively. Two samples with different interaction times (t) were separated 
from the solution using magnetic confinement. Both samples were washed three times, 
and then re-suspended in PBS for TEM analysis. The mixture was then applied in an 
external magnetic field (0.2 T) for 1 min. After washing twice, the magnetic confined 
complex was re-suspended with PBS. 
4.2.6 Analysis of the antibacterial effect 
The antibacterial property of Gm-FMNP1 to E. coli was analyzed by using plate counting 
technique. Typically, 200 µL of the above bacterial solution and NPs mixture were 
spread homogeneously onto agar plates. All the agar plates were then incubated overnight 
at 37 °C. The number of CFU of the bacteria was calculated following the incubation. 
The antimicrobial efficiency of Gm-FMNPs to E coli was further investigated by 
standard agar disc diffusion. Briefly, one isolated E. coli colony was incubated overnight 
in fresh broth at room temperature to reach a bacterial culture of ~107 CFU/mL. A 200 
µL aliquot of this culture (~105 CFU/mL) was spread onto agar plates. Sterile filter paper 
discs (7 mm) immersed in 1 mL PBS containing different standard concentrations of free 
Gm and FMNP1 solution samples (both conjugated with or without Gm) were then 
applied to the plates and incubated for 18 h at 37 °C. The antibacterial efficiency of the 
Gm-FMNPs was then determined as a function of E. coli colony inhibition diameters 
based on the calibration exponential curve obtained in experiments with known 
concentrations of the standard solutions. 
4.2.7 Determine the concentration of gentamicin on the FMNP1 
The amount of gentamicin conjugated on the GM-FMNPs was determined via an o-
phthalaldehyde assay reported by C. Lecároz with slight modification.47 In brief, the o-
phthalaldehyde reagent was formulated by adding 25 mg of o-phthalaldehyde, 625 µL of 
methanol and 30 µL of mercaptoethanol to 5.6 mL of sodium borate (0.04 M, pH 9.7) 
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under dark for at least 24 h at room temperature. This reagent should be used in 48 h. 
Standard concentrations of gentamicin sulfate were prepared by serial dilution with 
borate buffer at concentrations of 50, 25, 12.5, 6.25, 3.1, and 1.5 µg/mL. The 
concentrations of gentamicin in the GM-FMNPs were measured by spiking the NPs in 
the borate buffer (1 mg/mL). Then, o-phthalaldehyde reagent, gentamicin solutions 
(standard solutions and NPs solutions), and isopropanol were mixed in similar 
proportions and stored for 30 min at room temperature. The amount of gentamicin was 
evaluated by measuring the adsorptions at 292 nm (Shimadzu 3600 UV-visible 
spectrophotometer) to obtain a standard adsorption curve relating to gentamicin 
concentration. The concentrations of gentamicin in the NPs solution were calculated by 
means of the standard curve. 
4.2.8 Preparation of thin section samples for TEM analysis 
In the initial experiment, thin section treated samples were prepared for TEM/EDX to 
confirm the interaction of Gm-FMNP1 with bacteria E. coli. The samples were prepared 
by fixing the above bacteria-NPs complex (E. coli incubated with and without Gm- 
FMNPs for 20 min and 60 min, respectively) with 2.5% (v%) glutaraldehyde in sodium 
cacodylate buffer (0.1 M, pH 7.4). After 2.5 h fixation, the cells were washed three times 
in cacodylate buffer with centrifugation (~ 4500 g for 6 min), and further fixed with 1% 
osmium tetroxide in a cacodylate buffer solution for 1 h. The samples were washed again, 
and the final pellets were placed in drops of 5% Noble agar. The samples were further 
fixed in 2% uranyl acetate for 2 h, followed by dehydration in an ethanol solution with 
ascending gradients of strength (50%, 70%, 85%, 95% with two changes in absolute 
ethanol, 15 min each). The specimens were then washed in propylene oxide twice and 
infiltrated with an EPON resin: propylene oxide mixture (ratio 1: 1 and 3: 1, placed in 
each once) and twice in pure EPON resin. Sample resin blocks were prepared by 
embedding the samples in resin and polymerizing them at 60 °C for 2 days. The resin 
blocks were then trimmed and sectioned (80–100 nm) on a Reichert Om-U3 
ultramicrotome with a diamond knife. Ultrathin sections were placed on 200-mesh 
formvar/carbon-coated nickel (Ni) grids for further TEM/EDX analysis. 
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4.3 Results and Discussion  
4.3.1 Characterization 
The morphology of both FMNPs was characterized by TEM as shown in Figure 4.2. An 
obvious boundary between the core and the shell is observed in most of the particles. For 
FMNP1, the average diameter of the iron oxide core is estimated to be 50 ± 8 nm, while 
the thickness of the silica shell is estimated to be 12 ± 5 nm (Figure 4.2a). The mean 
particle size is approximately 65 ± 8 nm.  For FMNP2, the average diameter of 
monodispersed IONPs is 18 ± 2 nm (Figure 4.2b). The average diameter of the core-shell 
FMNP2 is about 30 ± 5 nm, and the shell is estimated at 5 ± 2 nm.  
 
 
83 
 
 
Figure 4.2 TEM micrograph of the core–shell structures of FMNP1 (a) and FMNP2 (b). 
The core-shell structured both FMNPs was further investigated through the XRD. As 
shown in Figure 4.3, the typical peak of semi-crystalline SiO2 is broad and can be found 
around 23° (2 θ). The other positions (labelled) and intensity of the peaks are coincident 
with XRD pattern for bulk Fe3O4 or α-Fe2O3 phase with cubic inverse spinel structure 
(JCPDS file 39-1346 and 190629, respectively). Thus, combining the TEM images, the 
semi-crystalline SiO2 shell has a lighter color in the TEM micrograph, whereas the Fe3O4 
or α-Fe2O3 core has higher electron density, and therefore, has a darker color. For 
FMNP2, we also examine the oxidation status of FMNP2 by XANES. The results show 
the Fe K-edge in the XANES spectra of the standard Fe3O4 sample and FMNPs (Figure 
A3, from Appendix 3). The Fe K-edge excitation threshold (E0) is the maximum of the 
first derivative of the XANES spectra. Clearly, the FMNPs have the same E0 as that of 
Fe3O4. Thus, the core of the FMNPs is attributed to Fe3O4. 
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Figure 4.3 XRD profiles of the core-shell structured (a) FMNP1 and (b) FMNP2 
Magnetite (Fe3O4) NPs are known for their unique superparamagnetic property at room 
temperature 48. As shown in Figure 4.4, typical hysteretic loops for superparamagnet are 
found for both FMNPs by VSM analysis, which indicate both particles exhibit 
superparamagnetic property. Our calculation shows the saturation magnetization (Ms) at 
room temperature of FMNP1 and FMNP2 are 2.512 emu/g and 1.5955 emu/g, 
respectively. In comparison with other Fe-based magnetic materials, Fe3O4 has high 
thermal stability with a high Curie temperature (Tc) of 858 K. Figure 4.4 shows the 
superparamagnetic behavior of the FMNPs during field cooling (FC) and zero-field 
cooling (ZFC) from SQUID analysis. The results indicate the blocking temperatures of 
FMNP1 and FMNP2 are at 120 K and 115 K, respectively.  
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Figure 4.4 Characterization of magnetic property. VSM measurement of hysteresis loops 
of FMNP1 (a) and FMNP2 (b); SQUID analysis of zero-field-cooled (ZFC) 
magnetization curve of FMNP1 (c) and FMNP2 (d) at 50 Oe. 
Fourier Transform Infrared Spectroscopy (FTIR) was further carried out to confirm the 
formation of silica shell and bioconjugation of Gm to FMNP1. As shown in Figure 4.5, 
Si-O-Si stretch is found at 1070 cm-1. Furthermore, the typical –CH2 stretch at 2930 cm-1, 
the –C=N stretch of the imine group, and –C=N–R at 1640 cm-1 appears in the spectrum 
of Gm-FMNP1. No –C=O stretch at 1760 cm- is found after Glu linking the FMNPs and 
Gm. Similar results were also found for Gm-FMNP2 (data not shown). 
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Figure 4.5 FTIR absorption spectra of FMNP1, glutaraldehyde (Glu) modified FMNP1 
(Glu-FMNP1), and Gm-FMNP. 
4.3.2 Capture, detection and decontamination of E. coli by Gm-
FMNP1 
It should be noted that, in our initial experiment, Gm-FMNP1 was prepared for capturing 
bacteria E. coli. As shown in Figure 4.6, Gm-FMNP1 (1 mg) are found to capture and 
remove E. coli cells (1 x 107 CFU/mL) under an external magnetic field of 0.2 T. 
Specifically, approximately 90% of the Gm-FMNP1 can be separated from the solution 
within 6 min, and almost no E. coli cell is found in the suspension after 20 min of 
magnetic confinement. 
 
Figure 4.6 Magnetic capture of bacterium E. coli under external magnetic field. 
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We further used fluorometer and fluorescent microscopy to confirm the capability of Gm-
FMNP1 for bacteria capture. For Gm-FMNP1, the maximum fluorescent emission (λem) 
measured by a fluorometer is at 517 nm with an excitation wavelength of 492 nm, while 
free FITC with λem = 513 is shown in Figure 4.7a. After mixing with E. coli cells for 20 
min (1 x 103 CFU/mL), a broad emission peak with a substantial decrease in intensity is 
observed for Gm- FMNPs. It is also found that the peak has a slight red-shift to λem at 528 
nm. No significant change is observed over time. This decreasing in fluorescent intensity 
and red shift could be attributed to formation of aggregation between NPs and bacterial 
cells, which cause inner filter effect to suppress the blue side of emission spectrum by re-
absorption of photons.49 Through fluorescent microscopy, we can further confirm the 
formation of aggregation. Figure 4.7b-2 shows clearly that E. coli cells attached to Gm-
FMNPs are aggregated in solution, while there is no aggregation when the E. coli were 
incubated with FMNPs alone (Figure 4.7b-1). Therefore, it clearly shows that Gm-
conjugated with FMNPs are able to recognize very low concentrations of E. coli. 
We then used TEM to study the capability of Gm-FMNP1 to capture E. coli. FMNP1 
without Gm were used as the negative controls, including FMNP1, glutaraldehyde (Glu)-
FMNP1, and ethanolamine (EA)-FMNP1. From Figure 4.8, we found that the bacterial 
cells were attached with the aggregation of dark dots in the mixture of Gm-FMNP1 and 
E. coli.  It is interesting that instead of the central cylindrical region of the cell, the cell 
poles (dark hemispheres) are more aggressively attacked by Gm-FMNP1. No interaction 
between E. coli cells and the negative control samples was found (Figure 4.8). TEM-
EDX analysis of thin section samples (Figure 4.8e) clearly shows that the dark dots 
interacting with E. coli contain iron (Fe) from the core of the FMNP1 and silicon (Si) 
from the mesoporous silica shell. The peaks of nickel (Ni) stem from the TEM sample 
grid. Thus, these dark dots are attributed to FMNP1 (Figure 4.8 d). It is believed Gm has 
strong interaction with lipopolysaccharides on the Gram-negative bacterial cell wall,50, 51 
while EA is inert towards E. coli. We can conclude that Gm-FMNP1 can recognize and 
attach with the surface of E. coli cell because of the linkage of Gm to E. coli cell surface. 
This attachment mediates the capturing of bacterial cells. 
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Figure 4.7 (a) Fluorescent spectra of free FITC, FMNP1, and the Gm-FMNP1 
before/after detecting E. coli cells (1x103 CFU/mL); (b1) FMNP1 mixing with E. coli, 
1x103 CFU/mL, (with dark field (DF, left) and bright field (BF, right); (b2) E. coli 
interacting with Gm-FMNP1 with dark field (DF, left) and bright field (BF, right) when t 
= 20 min. 
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To further investigate the interaction between Gm-FMNP1 and E. coli, we measured the 
samples of bacteria and NPs which were cultured for 20 min and 60 min as shown in 
Figure 4.8b and c, respectively. The interaction between Gm-FMNP1 and E. coli cells is 
observed (indicated by a blue arrow) when the interaction time (t) is 20 min, maintaining 
the integral ‘‘envelope’’ structure. However, the areas of the cell wall to which the Gm-
FMNP1 attach exhibit texture changes (see the small insert in Figure 4.8b). Significant 
disruption of the membrane and cell lysis occur with an increase in the interaction time 
from 20 to 60 min. Figure 4.7c shows that the bacterial cell membranes are broken and 
the cytoplasmic matrix appears to be leaking out. Such phenomena are not observed in 
samples of bacteria mixed with negative control samples, i.e. FMNP1 (Figure 4.8a), Glu- 
FMNP1, and EA-FMNP1, respectively. Furthermore, no bacterial cells with an integral 
structure are observed using TEM when the sample was incubated for 3 h. Previous 
report indicated that the polycationic from gentamicin could induce strong cell wall-
adsorption at an early stage.51 After that, cationic Gm may rearrange the 
lipopolysaccharide packing order through ionic bonding, consequently disrupting 
bacteria’s outer membrane and promoting membrane permeability.52, 53 Thus, in our 
study, it is likely that the Gm- FMNP1 attach and damage the cell wall first, and are then 
adsorbed within the cell. 
The response of E. coli to the Gm-FMNP1 was further studied by calculating the colony-
forming units (CFU) of both supernatants and precipitates. A cultured E. coli sample was 
used as a positive control. Negative controls are FMNP1 without Gm, i.e. FMNP1, Glu-
FMNP1, EA-FMNP1. Diluted E. coli cells were incubated with Gm-FMNP1 and 
negative controls for 30 min, respectively. We found no significant precipitation is 
observed in the E. coli suspensions mixed with negative controls: FMNP1s, Glu-FMNP1, 
and EA-FMNP1, respectively. However, obvious precipitation can be found in the E. coli 
suspension mixed with Gm-FMNP1. To evaluate the antibacterial activity of Gm-
FMNP1, all samples were washed and freeze-dried several times to remove free Gm from 
the sample. 
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Figure 4.8 Analysis of the interaction between NPs and bacterium E. coli. (a), TEM 
image of E. coli mixing with FMNP1 without Gm conjugation. (b) E. coli mixing with 
Gm-FMNP1 with less than 20 min of interaction time (t). (c) E. coli interacting with Gm-
FMNP1 when t = 60 min. (d) Thin section TEM analysis of E. coli mixing with Gm-
FMNP1 when t = 20 min. (e) The TEM-EDX spectrum of the Gm-FMNP1. (f) Thin 
section TEM analysis of E. coli mixing with Gm-FMNP1 when t = 60 min. 
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Figure 4.9 shows photographs of the resulting colonies in agar plates for all samples. The 
cultured E. coli mixed with FMNP1 (Figure 4.9a-A2), Glu-FMNP1 (Figure 4.9a-A3), and 
EA-FMNP1 (Figure 4.9a- A4), respectively, show a similar result with the positive 
control (Figure 4.9a-A1); whereas Gm-FMNP1 (0.1 mg) significantly inhibit the growth 
of E. coli. No living cells can be found throughout the suspension of E. coli mixed with 
Gm-FMNP1 as shown in (Figure 4.9a-A5 and -A6). Further analysis indicates that the 
bacterial concentration of those FMNP1 without Gm is 0.8 x 103 CFU/mL, which is 
similar to the positive control (1.0 x 103 CFU/mL). However, the bacterial concentration 
decreases dramatically in the sample of Gm-FMNP1 as shown in Figure 4.9b. The results 
confirm that Gm-conjugation is playing the key role to allow the FMNP1 to interact with 
E. coli. The antimicrobial susceptibility of E. coli to Gm-FMNP1 was further determined 
by the agar disk diffusion method with the comparison of the calibration curve obtained 
by testing pure Gm (Figure 4.9c). Here, 0.1 mg of Gm-FMNP1 shows a similar 
antimicrobial efficiency to 12–15 mg of pure Gm. Our experimental results indicate that 
~ 8 µg of Gm could be conjugated on 0.1 mg FMNP1 (Figure A4 and Table A1, from 
Appendix 4). Furthermore, Gm- FMNP1 are able to maintain their bioactivity, even when 
stored at 6 °C for 3 months.  
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Figure 4.9 Antimicrobial efficiency of Gm-FMNP1 (0.1 mg/mL) with E. coli (~1.0 x 103 
CFU/mL) in 1 mL solution. (a) Plate counting of (A1) E. coli alone, (A2) E. coli mixed 
with FMNP1, (A3) Glu-FMNP1, (A4) EA-FMNP1, (A5) the upper-level liquid of Gm-
FMNP1 interacting with E. coli, and (A6) the precipitate of E. coli mixed with Gm-
FMNP1; (b) calculation the number of colony-forming unit (CFU) of all samples. (c) The 
agar-diffusion assay. In the small inset image, No. 2 to No. 7 represent a 2-fold serial 
dilution of Gm solutions (from 6.25 to 200 mg/mL). No. 1, No. 8, No. 9 and No. 10 refer 
to the negative controls with PBS solution, EA-FMNP1 solution and Gm-FMNP1 
solution stored in a fridge for 3 months, Gm- FMNP1 were freshly prepared. In all cases, 
the concentration of NPs is 0.1 mg/mL. 
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4.3.3  Ubiquitous capture of bacteria by Gm-FMNP2 
We further developed an updated Gm modified NPs (Gm-FMNP2) for ubiquitous capture 
of bacteria. We first mixed Gm-FMNP2 with bacterium E. coli. As expected, TEM image 
shows clearly the attachment of NPs with bacterial cells (Figure 4.10a). We further 
analyze the ability of Gm-FMNP2 for capturing Gram-positive bacterium S. aureus. As 
discussed above, Gm in known to be uptaken by susceptible Gram positive bacteria such 
as S. aureus strain and kill the bacterium under the regulation of membrane potential and 
electrochemical gradient.54, 55 The uptake of gentamicin by S. aureus is reported 
involving of ionic adherence to the cell surface and subsequently binding to a membrane 
aerobic energization complex.43 Phospholiplids and teichoic acid on the surface of Gram-
positive bacteria were supposed to be the initial binding site for aminoglycoside 
antibiotic.56, 57 Thus it is expected that our Gm modified NPs can interact with S. aureus, 
and hence capture and separate bacterial cells from solution under external magnetic 
field. As shown in Figure 4.10b, TEM image shows Gm-FMNP2 were found to bind on 
the surface of the S. aureus. Furthermore, in the EA-FMNP2 and S. aureus group, we did 
not find the interaction between the particles and bacteria. 
 
Figure 4.10 TEM micrographs of capture of bacteria E. coli and S. aureus by Gm-
FMNP2. 
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In our study, the bacteria capture experiment in our study was done by mixing Gm-
FMNPs with S. aureus for desired time. Although one hour incubation Gm-FMNP2 with 
bacteria could reach maximum capture effect, we could also find a few bacteria even 
after 10 min mixing through optical microscopy. In addition, as discussed above, the Gm-
FMNP2 exhibit a smaller hydro-diameter and better magnetic property, due to a smaller 
core with good crystalline structure and thinner silica shell. Good magnetization can 
result in fast confinement of particles. Consistently, we observed the bacterium-NPs 
complex (aggregation) can be confined even in 1 min under external magnetic field of 0.2 
T. Using the optical microscopy, we found that the diluted S. aureus with the 
concentration as low as 0.5×103 CFU/mL can be separated from the solution by the 
core-shell MNPs in 1 min. Further quantitative analysis of the capture efficiency, 
detection limitation and possible toxic effect of Gm-FMNP2 to S. aureus are under study. 
4.4 Conclusion 
In sum, we have demonstrated an efficient and fast way for ubiquitous capture, detection 
and decontamination of bacteria, by conjugating antibiotic gentamicin to fluorescent 
magnetic nanoparticles (FMNPs). Two different methods were developed for synthesis of 
FMNPs, including a one-pot co-precipitation approach and two-step thermal 
decomposition method. TEM results show that the FMNPs prepared by both methods 
comprise of a Fe3O4 core and a silica (SiO2) shell. Both Gm conjugated FMNPs show a 
typical superparamagnetic property. Preliminary results show that Gm-FMNP1 can 
capture bacterium E. coli up 90 % of bacterium cells in a concentration of 1x 107 
CFU/mL within 20 min. The detection limit was found to be as low as to a concentration 
of 1 x 103 CFU/ mL through optical microscopy analysis. The antibacterial effect of Gm-
FMNP1 to E. coli was further demonstrated by plate counting technique and the 
efficiency was found 20 % enhanced. Furthermore, Gm-FMNP2 prepared by two-step 
method with a better crystalline structure and magnetization, show higher capture 
efficiency for capturing both gram-negative bacterium E. coli and Gm sensitive Gram-
positive bacterium S. aureus. By improvement of particles stability through efficient 
functionalization, we estimate that the Gm-FMNPs can be a promising platform for 
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simultaneous rapid capture, sensitive detection, and decontamination of bacteria for 
disease control in clinic and wastewater treatment. 
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CHAPTER 5 
DEVELOPMENT OF LUCIFERASE CONJUGATED 
GOLD NANOPARTICLES IN DETECTION OF 
THROMBIN 
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5.1 Introduction 
Fluorescent labels have been widely used in modern biotechnology. For example, directly 
labelling of biomolecules with fluorophore can locate molecules inside cell or provide 
signal for immunoassay. However, biological activities are often involved in dynamic 
processes, including protein interactions, ligand-receptor binding, changes of proteins and 
nucleic acid conformation in response to stimulus. One signal obtained by simple 
labelling is hard to provide more information. In this case, extensive using of fluorescent 
labels in the form of Förster/fluorescence resonance energy transfer (FRET) provides a 
powerful tool to probe those biological processes. 
FRET is a process in which nonradiative energy is transferred from an excited 
luminescent fluorophore (sever as a donor) to a proximal ground state fluorophore (sever 
as an acceptor, typically in a few nanometers away).1 The energy transfer efficiency (E), 
which is defined as the fraction of energy transfer event occurring per fluorophore donor 
excitation event, is thus distance dependent, as shown in the equation (5.1) below, 
E = 1
�1+�
r
R0
�
6
�
                                                       (5.1) 
where r is the distance between two partners and R0 is the distance at which the resonance 
energy transfer (RET) efficiency is 50% and represents a characteristic parameter for the 
given partners. As a result, this process can be used as a “molecular ruler”, allowing one 
to determine the distance between partners by measuring the changes of fluorescent 
signal from the donors or acceptors. 
FRET is a very sensitive and reliable technique widely used in biosensing. In particular, 
detecting analytes can be achieved by using the ratio of the two different fluorescent 
intensities. This could eliminate most ambiguities in the detection caused by external 
assay factors such as excitation source fluctuations and sensor concentration.2, 3 
In conventional FRET system, both the donor and the acceptor are fluorescent agents. 
However, the process of RET can also involve bioluminescent and chemiluminescent 
donor, or nonluminescent acceptors. In particular, bioluminescence resonance energy 
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transfer (BRET) which is operated by biochemical energy generated by bioluminescent 
protein to excite fluorophore offer additional advantages over FRET, including intrinsic 
low background, less signal interference and no photobleaching issue. The reason for 
those aspects is that BRET does not require external light source. In addition, BRET 
possesses less harmful to biological system comparing to FRET and chemiluninescence 
resonance energy transfer (CRET), as the reaction to produce light is a nature 
biochemical process. 
Traditionally, fluorophores such as fluorescent dyes are used in RET systems. However, 
fluorescent dyes have several drawbacks such as photobleaching and high sensitivity to 
environmental factors. In recent, a number of studies have incorporated nanoparticle into 
the design of RET system with enhanced RET performance and flexibility in the 
selection of excitation source. Nanoparticles (NPs), such as gold nanoparticles (Au NPs) 
and quantum dots (QDs), possess unique optical properties and can act either a quencher 
(a special acceptor) a fluorescent donor (and acceptor), respectively. 
Au NPs can serve as excellent fluorescence quenchers (acceptor) for RET based assay 
because of their extraordinary molar extinction coefficients and broad energy absorption 
bandwidth in the visible range.4, 5 In addition, the unique chemical reactivity of gold 
allows Au NPs to be a suitable platform to selectively binding of a wide range of organic 
or biological fluorescent ligands for detecting small molecules and biological targets. The 
most common set-up for Au NPs based RET assay is the fluorescence quenching-based 
switch on/off. For example, fluorescence (or bioluminescence) of the donor is quenched 
on attaching with Au NPs. The presence of analytes results in release (or extends the 
usable distances) of donor from Au NPs and hence restores the fluorescence (or 
bioluminescence), of which the intensity is proportional to the amount (concentration) of 
analytes. In the last decades, a number of innovative approaches using Au NPs as 
quencher in RET system have been developed for the detection of metal ions,6-8 small 
molecules,9, 10 nucleic acids 11 and enzymes.12, 13 
Bioconjugated nanoparticles have proven to be extremely convenient and invaluable tools 
for biomedical applications over last decades. Apart from using as excellent drug/gene 
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delivery cargoes and bio-imaging agents, bioconjugated nanoparticles have also been 
used to create nanosensors of extremely sensitivity and highly specificity in analysis of a 
variety of biological analytes. Among the most important biological analytes are 
protease, a group of enzymes that selectively cleave peptide bonds in proteins and 
polypepetides via hydrolysis.14-17 Proteases not only play a crucial role in a number of 
biological processes, including hormone activation, blood coagulation and apoptosis, but 
also are involved in many diseases, such as viral infection, cancer, and inflammatory 
disease. The development of approaches for detecting and real time monitoring of 
protease is of great interest as they can be biomarker for certain disease.17 
One of important proteases is thrombin. Thrombin is a serine protease that plays a central 
role in haemostasis by converting soluble fibrinogen to fibrin clot.18, 19 Thrombin has 
been reported involved in variety of diseases, such as rheumatoid arthritis,20 pulmonary 
fibrosis 21 and glomerulonephritis. 22 The concentration of thrombin in both blood and 
urine of health bodies is almost undetectable, as it exhibits in the form of prothrombin (or 
thrombin-antithrombin complex).23, 24 However, it can reach to low micromolar level 
during coagulation process and early haemostatic process in plasma.23 In the urine 
samples from glomerulonephritis patients, even low level of thrombin has been 
generated.24 A number of strategies have thus been developed for sensing and monitoring 
thrombin, including antibody based radioimmunoassay/ELISA,23 fluorophore labelled 
substrate bound sensor,25-28 and recent developed nucleic acid probes based 
aptamersensor.29-31 Among them, peptide substrate reporters offer a lot advantages, as 
they response only to the active thrombin and thus avoid false positive from prothrombin. 
In addition, fluorophore labelled peptide substrate can be further incorporated into NPs 
based RET system to enhance the sensitivity and reduce assay time.  
In this section, we report the development of a nanosensor based on luciferase conjugated 
gold nanoparticles for sensing thrombin in both buffer and urine samples. The advantage 
of using urine samples is that urine samples can be easily and repetitively obtained 
avoiding problems and risks associated with blood sampling. In addition, as the presence 
of thrombin activity in urine is reported to be associated with glomerulonephritis, it is 
possible to provide useful information for diagnosis of diseases related to kidney.24 
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5.2 Experimental section 
5.2.1 Design of the pRluc-Au NPs nanosensor 
In this study, the design of the nanosensor for detection of thrombin concentration is 
shown in Figure 5.1. The nanosensor is composed of a conjugate of alkanethiol ligand 
stabilized gold nanoparticles (Au NPs) and a recombinant protein pRluc that containing a 
domain of Renilla luciferase (Rluc) and a short peptide as the sensing element. Au NPs 
have been demonstrated for its strong quenching effect for emission from proximate 
organic fluorophores,32 fluorescent proteins,33 QDs 34 and even bioluminescence 35 in 
RET system. Thus, in this system, the initial bioluminescence generated by the pRluc is 
quenched due to proximal conjugation with Au NPs. However, in the presence of 
thrombin, the sensing peptide is cleavage, which result in release of Rluc from 
nanoparticles and hence generate bioluminescence. 
 
Figure 5.1 Schematic diagram of detection of thrombin via pRluc conjugated gold 
nanoparticles 
The details of the experiment are described below. Unless otherwise stated, chemicals 
were obtained from Sigma-Aldrich. Only NANOpure water (ρ=18.2 MΩ) was used. 
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5.2.2 Dihydrolipoic acid (DHLA) synthesis  
DHLA was synthesized by reduction of thioctic acid (TA) according to a published 
procedure.36 Briefly, NaBH4 (1.2 g) was added by small portions into an aqueous solution 
of TA (6 g in 117 mL of 0.25 M sodium bicarbonate solution). The mixture was stirred 
vigorously under cold bath (~ 4 °C) for 30 min. Afterwards, the mixture was acidified to 
~ pH 1.0 by addition of HCl. DHLA was extracted three times from the crude product by 
20 mL of toluene. The organic phase was washed by water and dried under vacuum oven. 
The purified DHLA was stored at room temperature under vacuum. 
5.2.3 Synthesis and functionalization of Gold Nanoparticles 
Gold nanoparticles were prepared via the sodium citrate reduction of HAuCl4·3H2O as 
described by Frens et. al. 37 with slight modification. In brief, one hundred millilitres of 1 
mM HAuCl4·3H2O in water was heated until refluxing under stirring. Following that, 5 
mL of 38.8 mM sodium citrate tribasic dehydrate with water was added quickly into the 
solution under vigorously stirring. The mixture was then kept under refluxing for another 
15 min. The color of the solution turned from yellow to clear, black, purple and to deep 
red eventually. Afterwards, the mixture was removed from heating and cool to room 
temperature. The resultant solution was then filter through 0.45-μm acetate filter to 
remove large agglomerates and stored at room temperature under dark.  
Citrate-stabilized gold nanoparticles were further functionalized by alkanethiols, i.e. 11-
mercaptoundecanoic acid (MUA) and DHLA. In following experiment, only MUA is 
used in description of the procedure. Typically, a solution of 3 mL of the above citrate-
stabilized gold nanoparticles (15 nM, pH adjusted to 10.0 by 0.5 M NaOH) was mixed 
with 0.5 mL ethanol. Afterwards, a solution of 0.5 mL ethanol dissolved with MUA (10 
mM) was added in the gold solution and stirred for 19 h. The mixture was then filtered 
through 0.45-μm acetate filter. The MUA modified gold nanoparticles were further 
purified by amicon ultral filters (Ultra-0.5 mL). Finally, the MUA modified particles 
were re-suspended in 1 mL DDW (~ 60 nM). 
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5.2.4 Plasmid constructions 
A recombinant protein containing Renilla luciferase (Rluc) and a short peptide sequence 
as thrombin substrate was constructed as following. Firstly, Rluc gene from the plasmid 
pRL-null (Promega, Inc) was cloned into the MCS site of pET 32-a (Merck Millipore 
Inc.) plasmid under two restriction sites (BamH I and Xho I). Two primers were designed 
for the cloning (forward: 5' AAAGGATCCAGCGGTGGTGGTGGTAGCATGAC 
TTCGAAAGTTTATGATCCAG; reverse: 5' TGTGCTCGAGTTGTTCATTTTTGA 
GAACTCGCTC 3'). As shown in Figure A5 (Appendix5), thrombin substrate originally 
from pET 32-a plasmid is thus located at upstream (N-terminal) of Rluc gene. A trx 
region from pET 32-a coding for thioredoxin protein is kept to maintain high level of 
recombinant protein expression.38 The bold underline in the forward primer indicates a 
six amino acid linker (SGGGGS) was inserted after Bam H I site to leave a flexible space 
for proper folding of Rluc protein.  
In a typical experiment, the PCR products and the plasmid were digested with relating 
restriction enzyme and purified through agarose gel, respectively. The digested DNA 
insert was ligated into the relating MCS site at the plasmid. The ligation product was 
transformed into E. coli BL21 cells. The successful construction of the plasmid was 
confirmed by DNA sequencing (Robarts Institute, Western University).  
5.2.5 Protein Expression and Purification  
The above bacterial cells with recombinant plasmid were grown overnight at 37 oC in 5 
mL of Luria Bertani (LB) broth containing 100 μg/mL ampicillin. This culture was used 
to further inoculate 500 mL of broth containing 100 μg/ml of ampicillin, and this was 
grown at 37 oC. When the culture reached an OD600 of 0.375, Isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added to 1 mM final concentration to induce the 
expression of recombinant protein pRluc and the bacteria were left to grow for 4 h at 
room temperature. The cells were harvested by centrifugation at 12,000 rpm for 5 min at 
4 oC. The pellet was resuspended in a binding solution (BS) of 20 mM Tris/HCl, pH 7.4, 
500 mM NaCl and 5 mM imidazole and sonicated on ice using 15-s bursts followed by 
30-s rest for 30 cycles using a Mandel Scientific Q500 sonicator (Guelph, Canada). The 
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suspension was centrifuged at 10,000 rpm at 4 oC for 30 min to collect the supernatant 
from bacterial cell pellet. The protein was purified via His-trap HP columns (GE 
lifescience, Inc.) by a syringe pump. The column was first equilibrated with BS. The 
supernatant containing the protein was loaded on the column, and the column was 
washed with 10 column volumes of the BS. The protein was eluted using BS with a 
gradient of imidazole from 20 mM to 200 mM) over 10 column volumes. Five milliliters 
fractions were collected. An SDS-PAGE was run to verify the fractions containing the 
fusion protein, which were pooled together. Excess imidazole was removed from the 
combined fractions by buffer exchange with excess amount of 10 mM Tris/HCl, pH 7.4 
using an amicon Ultra centrifugal filter (ultra-15, MWCO 10 kDa, Millipore Inc). The 
resultant pRluc protein solution was stored in aliquot at -20 oC. The concentration of the 
protein was determined by bicinchoninic acid (BCA) protein assay (Thermo scientific 
Inc). 
5.2.6 Bioconjugation of Au NPs by pRluc protein 
The bioconjugation was mediated 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide  
(EDC). In a typical experiment, MUA or DHLa modified Au NPs (10 μL at 60 nM), 
pRluc (10 μL at 0.2 mM) and EDC (10 μL at 1 mM) were mixed in 270 μL of water. The 
mixture was incubated at room temperature for 2 h under gently shaking. Afterwards, 10 
μL of ethanolamine was added to stop the reaction. The pRluc Au NPs were further 
purified by amicon ultra-0.5 filter. 
5.2.7 Characterization 
Transmission electron microscopy (TEM) was used to analyze the morphology of the as-
made nanoparticles. The TEM images were obtained using a Philips CM-10 microscopy 
operating at 100 kv. The modification of nanoparticles by PE and QDs were verified by 
using Fourier transform infrared (FTIR) spectrophotometer (Bruker FTIR-IFS 55, 
Germany). UV-visible absorption spectra were recorded by UV-3600 spectrophotometer 
(Shimadzu, Japan).  
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5.2.8 Thrombin assay 
The pRluc-Au NPs conjugate (50 μL at 1 5 mM) was mix ed  with 1 0 mM Tris bu ffer 
(TBS, 240 μL, pH 7.4). The assay was initiated by addition of thrombin (from human 
plasma, 1000 NIH U/mg, 1 NIH unit is approximate equal to 0.3 µg in amount, 10 μL of 
each stock solution), giving final concentrations ranging from 3 ng/mL to 300 µg/mL. In 
a typical experiment, the reaction was incubated at room temperature for 1 h. 
Bioluminescence emission spectra were collected immediately following addition of 1 μL 
of CTZ (10 mg/mL in ethanol) to the digestion solution, by a QuantaMaster™ 40 
Spectrofluorometer (PTI  Inc., London, ON). 
For detecting the thrombin in urine, a fraction of fresh urine solution from health body 
(provided by Mr. GeYi Bao from St. Joseph’s Hospital) were first pretreated by 
centrifugation (6000 rpm, 15 min) and filtration (0.2 µm filter). The thrombin with 
different concentrations was then spiked into a solution of pretreated urine (10% in TBS). 
The pRluc-Au NPs conjugate (50 μL at 15 mM) was added into this solution. After 1 h, 
bioluminescence emission spectra were collected as described above.  
5.3 Results and Discussion 
5.3.1 Characterization of the pRluc-Au NP conjugate 
In our study, citrate stabilized Au NPs with an average diameter around 13 nm (Figure 
A6a, from Appendix 6) was first synthesized, followed by surface functionalized with 
alkanethiol molecules (MUA and DHLA in this study). The carboxyl group presented on 
the surface of nanoparticles is then used to conjugate with the purified pRluc (MW ~ 60 
kDa, Figure A6b at Appendix 6) via EDC medicated carbodiimide chemistry. Figure 5.2a 
shows the UV-visible spectra of unconjugated and pRluc conjugated Au NPs. The 
maximum absorption wavelength (λab max) for both citrate capped Au NPs and DHLA 
modified Au NPs are found at 520 nm as expected. Meanwhile, MUA-Au NPs exhibits a 
30-nm red shif in λab max, which indicates the formation of a slight aggregation of the 
NPs. Au NPs are favorable for chemical absorption of alkanethiol. However, the 
monothiol ligands modified colloidal gold can undergo irreversible aggregation, partially 
due to the desorption of thiol from NPs surface.39 In addition, in a partially formed self-
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assembled monothiol layer, long methylene groups of alkanethiol ligands render the NPs 
with hydrophobic character, thereby promoting their aggregation.40 However, the 
disulfide group from DHLA offers higher affinity for the ligand to bind and stabilize Au 
NPs, resulting in a homogenous colloidal solution. Conjugation of pRluc to MUA-Au 
NPs causes a slight red shift of λab max and a broader absorption spectrum, which might be 
due to the cross-link of a pRluc molecule with several Au NPs. 
We further used FTIR to investigate the conjugation of pRluc with Au NPs. As shown in 
Figure 5.2b, citrate capped Au NPs shows a strong –OH stretch at 3500 cm-1. After 
modification with alkanethiol ligands (only MUA modified Au NPs was showed here), a 
peak is found around 1700 cm-1, which is attributed to –COOH group. A new band at 
1640 cm-1 is found in the pRluc-Au NPs sample, which is due to the stretch of peptide 
bond –CO-NH-. Thereby, we can conclude the pRluc is successful conjugated to Au NPs. 
5.3.2 Assay optimization 
We first tested the feasibility of the assay for detecting thrombin. Figure 5.3 shows that 
the bioluminescence is quenched while conjugating pRluc onto Au NPs. It should be note 
that, the RET only occurs when two partners approach very close to each other.41 Thus, 
we did not observed any quenching of bioluminescence found in a mixture of pRluc and 
Au NPs, without conjugation (data not shown). Furthermore, we found the recovery of 
bioluminescence while adding thrombin to pRluc-Au NPs. It is expected this recovery of 
bioluminescence is related to the concentration of thrombin, as more thrombin will free 
more pRluc from Au NPs surface. In order to obtain a best correlation of the 
bioluminescence signal to the analyte amount, we then test the factors that may affect the 
assay performance. 
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Figure 5.2 (a) UV-visible spectra and (b) FTIR spectra of bare Au NPs, alkanoethiol acid 
functionalized Au NPs and pRluc conjugated Au NPs 
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Figure5.3 Bioluminescent spectra of pRluc-Au NPs conjugates. 
We first test the alkanethiol ligands length effect.  In our study, alkanethiol ligands MUA 
(11 C) and DHLA (5 C) are used to control the distance between pRluc and Au NPs, 
respectively. As described above, RET ratio is reverse-proportional with distance 
between fluorophores.41 Thus, it is expected that the shorter linker of DHLA could have 
better quenching effect and result in higher recovered BL. However, our result (Figure 
5.4a) shows the recovered BL intensity from MUA (11 C) linker is 2-fold higher than that 
from DHLA. Two factors may contribute to the result. The first one might be more pRluc 
molecules released from NPs by thrombin in MUA modified Au NPs, as long chain of 
MUA gives more freedom between NP and protein for the access of thrombin to its 
substrate peptides. The other factor may be the dramatic loss of enzyme activity in the 
DHLA modified Au NPs due to conformation changes. Au NPs has been reported to 
cause the loss activity for enzymes absorbed to NPs surface by change their 
conformation.42, 43 Despites of lower stability of MUA Au NPs, the long chain of MUA 
may offer a steric barrier preventing the direct interaction between enzymes and Au NPs. 
On basis of this result, we then only use MUA modified Au NPs to conjugate pRluc in 
the following assay. 
We then optimized the bioconjugation process. We first examined the effect of ratio of 
pRluc and MUA-Au NPs to the recovery of BL, by fixing the amount of the conjugation 
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reagent EDC. Figure 5.4 b shows that the best molar ratio of pRluc to MUA Au NPs is 
10000:1. Then we fixed this ratio to analyze the effect of the ratio of EDC/MUA Au NPs 
to the rate of recovered BL. We found that high concentration of EDC could cause the 
aggregation of nanoparticles with decreasing of the recovered BL intensity. The best 
molar ratio of EDC to Au NPs is found at 10000:1 (Figure 5.4 c). Thus, the optimized 
molar ratio of MUA-Au NPs, pRluc and EDC is 1:10000:10000. 
We further analyzed the time effect on BL recovery by thrombin digestion. As shown in 
Figure 5.4d, the relative BL ratio reaches to its first peak after 30 min incubation. No 
significant changes in BL ratio with the incubation time from 1 h to 4 h. The recovered 
BL ratio is 20% higher by overnight incubation than that from 1 h incubation. However, 
to reduce the assay time, we determine the incubation time to one hour for our assay.  
 
Figure 5.4 The effect of (a) ligand length, (b) the molar ratio of Au NPs and pRluc, (c) 
the molar ratio of Au NPs and EDC, and (d) digestion time to the relative BL ratio. 
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5.3.3 Determination of thrombin concentration in both buffer and 
urine samples 
We then evaluated the capability of our nanosensor to measure the activity of thrombin 
under our optimized condition. As shown in Figure 5.5 a, increasing of thrombin 
concentration results in an increasing of the BL emission. A linear relationship between 
thrombin concentration and BL relative emission intensity is found in the rage of 300 
ng/mL to 300 µg/mL, which is under the range of thrombin in human blood 23. The limit 
of detection (LOD) for this assay is found to be 3 ng/mL. 
We then tested nanosensor for detection of thrombin in urine samples in order to test the 
influence of the biological matrix to our assay performance. By spiking the different 
concentration of thrombin and pRluc Au NPs in TBS with 10% urine from healthy 
subject, we did not find any significant changes for the overall assay performance in term 
of both detection limit and linear response, as shown in Figure 5.5b. Therefore, the results 
indicate that our nanosensor could be a potential tool for clinical diagnostic of thrombin 
related diseases. 
 
Figure 5.5 Detection of thrombin by using pRluc-Au NPs nanosensor in (a) TBS buffer 
and in (b) TBS buffer spiked with human urine. 
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5.4 Conclusions and Prospects 
In conclusion, we describe a bioluminescence nanosensor for highly sensitive 
determination of thrombin. A linear assay response is found between 300 ng/mL to 300 
µg/mL with LOD of 3 ng/mL in both buffer and urine samples. The detection of 
thrombin could be achieved in 15 min. The detection range is among the range of 
thrombin in Glomerulo-nephritis patients. The nanosensor can thus be a promising tool 
for clinical diagnostic of thrombin related diseases. 
5.5 References 
1. Roda, A.; Guardigli, M.; Michelini, E.; Mirasoli, M., Nanobioanalytical 
luminescence: Förster-type energy transfer methods. Analytical and Bioanalytical 
Chemistry 2009, 393, (1), 109-123. 
2. Kwon, J. Y.; Jang, Y. J.; Lee, Y. J.; Kim, K. M.; Seo, M. S.; Nam, W.; Yoon, J., 
A Highly Selective Fluorescent Chemosensor for Pb2+. Journal of the American 
Chemical Society 2005, 127, (28), 10107-10111. 
3. Mello, J. V.; Finney, N. S., Dual-Signaling Fluorescent Chemosensors Based on 
Conformational Restriction and Induced Charge Transfer. Angewandte Chemie 
International Edition 2001, 40, (8), 1536-1538. 
4. Sapsford, K. E.; Berti, L.; Medintz, I. L., Materials for Fluorescence Resonance 
Energy Transfer Analysis: Beyond Traditional Donor–Acceptor Combinations. 
Angewandte Chemie International Edition 2006, 45, (28), 4562-4589. 
5. Jain, P. K.; El-Sayed, I. H.; El-Sayed, M. A., Au nanoparticles target cancer. 
Nano Today 2007, 2, (1), 18-29. 
6. Huang, C.-C.; Chang, H.-T., Selective Gold-Nanoparticle-Based "Turn-On" 
Fluorescent Sensors for Detection of Mercury(II) in Aqueous Solution. Analytical 
Chemistry 2006, 78, (24), 8332-8338. 
7. He, X.; Liu, H.; Li, Y.; Wang, S.; Li, Y.; Wang, N.; Xiao, J.; Xu, X.; Zhu, D., 
Gold Nanoparticle-Based Fluorometric and Colorimetric Sensing of Copper(II) 
Ions. Advanced Materials 2005, 17, (23), 2811-2815. 
8. Huang, T.; Murray, R. W., Quenching of [Ru(bpy)3]2+ Fluorescence by Binding to 
Au Nanoparticles. Langmuir 2002, 18, (18), 7077-7081. 
9. Zhang, N.; Liu, Y.; Tong, L.; Xu, K.; Zhuo, L.; Tang, B., A novel assembly of Au 
NPs-β-CDs-FL for the fluorescent probing of cholesterol and its application in 
blood serum. Analyst 2008, 133, (9), 1176-1181. 
10. Chen, S.-J.; Chang, H.-T., Nile Red-Adsorbed Gold Nanoparticles for Selective 
Determination of Thiols Based on Energy Transfer and Aggregation. Analytical 
Chemistry 2004, 76, (13), 3727-3734. 
11. Dyadyusha, L.; Yin, H.; Jaiswal, S.; Brown, T.; Baumberg, J. J.; Booy, F. P.; 
Melvin, T., Quenching of CdSe quantum dot emission, a new approach for 
biosensing. Chemical Communications 2005, (25), 3201-3203. 
 
 
115 
 
12. Xia, X.; Yang, M.; Oetjen, L. K.; Zhang, Y.; Li, Q.; Chen, J.; Xia, Y., An 
enzyme-sensitive probe for photoacoustic imaging and fluorescence detection of 
protease activity. Nanoscale 2011, 3, (3), 950-953. 
13. Lee, S.; Cha, E.-J.; Park, K.; Lee, S.-Y.; Hong, J.-K.; Sun, I.-C.; Kim, S. Y.; Choi, 
K.; Kwon, I. C.; Kim, K.; Ahn, C.-H., A Near-Infrared-Fluorescence-Quenched 
Gold-Nanoparticle Imaging Probe for In Vivo Drug Screening and Protease 
Activity Determination. Angewandte Chemie International Edition 2008, 47, (15), 
2804-2807. 
14. Leung, D.; Abbenante, G.; Fairlie, D. P., Protease Inhibitors: Current Status and 
Future Prospects. Journal of Medicinal Chemistry 2000, 43, (3), 305-341. 
15. Zhang, B., Design of FRET-based GFP probes for detection of protease inhibitors. 
Biochemical and Biophysical Research Communications 2004, 323, (2), 674-678. 
16. Nelson, D. D. L.; Lehninger, A. L.; Cox, M. M., Lehninger Principles of 
Biochemistry. W.H. Freeman: 2013. 
17. Turk, B., Targeting proteases: successes, failures and future prospects. Nature 
reviews Drug discovery 2006, 5, (9), 785-799. 
18. Chang, J.-Y., Thrombin specificity. European Journal of Biochemistry 1985, 151, 
(2), 217-224. 
19. Shuman, M. A., Thrombin-Cellular Interactions. Annals of the New York Academy 
of Sciences 1986, 485, (1), 228-239. 
20. Bar-Shavit, R.; Benezra, M.; Eldor, A.; Hy-Am, E.; Fenton, J. W., 2nd; Wilner, G. 
D.; Vlodavsky, I., Thrombin immobilized to extracellular matrix is a potent 
mitogen for vascular smooth muscle cells: nonenzymatic mode of action. Cell 
Regulation 1990, 1, (6), 453-63. 
21. Hernández-Rodríguez, N. A.; Cambrey, A. D.; Chambers, R. C.; Gray, A. J.; 
McAnulty, R. J.; Laurent, G. J.; Harrison, N. K.; Southcott, A. M.; duBois, R. M.; 
Black, C. M.; Scully, M. F., Role of thrombin in pulmonary fibrosis. The Lancet 
1995, 346, (8982), 1071-1073. 
22. Kitamoto, Y.; Immura, T.; Fukui, H.; Tomita, K., Role of thrombin in mesangial 
proliferative glomerulonephritis. Kidney International 1998, 54, (5), 1767-1768. 
23. Shuman, M. A.; Majerus, P. W., The measurement of thrombin in clotting blood 
by radioimmunoassay. The Journal of Clinical Investigation 1976, 58, (5), 1249-
1258. 
24. Kitamoto, Y.; Tomita, K.; Imamura, T., Assessment of thrombin in the urine of 
glomerulonephritic patients by enzyme-linked immunosorbent assay. Annals of 
Clinical Biochemistry 2004, 41, (2), 133-137. 
25. Jaffer, F. A.; Tung, C.-H.; Gerszten, R. E.; Weissleder, R., In Vivo Imaging of 
Thrombin Activity in Experimental Thrombi With Thrombin-Sensitive Near-
Infrared Molecular Probe. Arterioscler Thromb Vasc Biol 2002, 22, (11), 1929-
1935. 
26. Tung, C.-H.; Gerszten, R. E.; Jaffer, F. A.; Weissleder, R., A Novel Near-Infrared 
Fluorescence Sensor for Detection of Thrombin Activation in Blood. 
ChemBioChem 2002, 3, (2-3), 207-211. 
27. Olson, E. S.; Whitney, M. A.; Friedman, B.; Aguilera, T. A.; Crisp, J. L.; Baik, F. 
M.; Jiang, T.; Baird, S. M.; Tsimikas, S.; Tsien, R. Y.; Nguyen, Q. T., In vivo 
 
 
116 
 
fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating 
peptides targeting thrombin activity. Integrative Biology 2012, 4, (6), 595-605. 
28. Lin, K. Y.; Kwong, G. A.; Warren, A. D.; Wood, D. K.; Bhatia, S. N., 
Nanoparticles That Sense Thrombin Activity As Synthetic Urinary Biomarkers of 
Thrombosis. ACS Nano 2013, 7, (10), 9001-9009. 
29. Huang, D.-W.; Niu, C.-G.; Qin, P.-Z.; Ruan, M.; Zeng, G.-M., Time-resolved 
fluorescence aptamer-based sandwich assay for thrombin detection. Talanta 2010, 
83, (1), 185-189. 
30. Tennico, Y. H.; Hutanu, D.; Koesdjojo, M. T.; Bartel, C. M.; Remcho, V. T., On-
Chip Aptamer-Based Sandwich Assay for Thrombin Detection Employing 
Magnetic Beads and Quantum Dots. Analytical Chemistry 2010, 82, (13), 5591-
5597. 
31. Zhao, Q.; Lu, X.; Yuan, C.-G.; Li, X.-F.; Le, X. C., Aptamer-Linked Assay for 
Thrombin Using Gold Nanoparticle Amplification and Inductively Coupled 
Plasma-mass Spectrometry Detection. Analytical Chemistry 2009, 81, (17), 7484-
7489. 
32. Dubertret, B.; Calame, M.; Libchaber, A. J., Single-mismatch detection using 
gold-quenched fluorescent oligonucleotides. Nature Biotechnology 2001, 19, (4), 
365-370. 
33. Hazarika, P.; Kukolka, F.; Niemeyer, C. M., Reversible Binding of Fluorescent 
Proteins at DNA–Gold Nanoparticles. Angewandte Chemie International Edition 
2006, 45, (41), 6827-6830. 
34. Kim, Y.-P.; Oh, Y.-H.; Oh, E.; Ko, S.; Han, M.-K.; Kim, H.-S., Energy Transfer-
Based Multiplexed Assay of Proteases by Using Gold Nanoparticle and Quantum 
Dot Conjugates on a Surface. Analytical Chemistry 2008, 80, (12), 4634-4641. 
35. Kim, Y.-P.; Daniel, W. L.; Xia, Z.; Xie, H.; Mirkin, C. A.; Rao, J., 
Bioluminescent nanosensors for protease detection based upon gold nanoparticle-
luciferase conjugates. Chemical Communications 2010, 46, (1), 76-78. 
36. Yonezawa, T.; Yasui, K.; Kimizuka, N., Controlled Formation of Smaller Gold 
Nanoparticles by the Use of Four-Chained Disulfide Stabilizer. Langmuir 2000, 
17, (2), 271-273. 
37. Frens, G., Controlled nucleation for the regulation of the particle size in 
monodisperse gold suspensions. Nature 1973, 241, (105), 20-22. 
38. LaVallie, E. R.; DiBlasio, E. A.; Kovacic, S.; Grant, K. L.; Schendel, P. F.; 
McCoy, J. M., A thioredoxin gene fusion expression system that circumvents 
inclusion body formation in the E. coli cytoplasm. Nature Biotechnology 1993, 
11, (2), 187-193. 
39. Schroedter, A.; Weller, H., Ligand Design and Bioconjugation of Colloidal Gold 
Nanoparticles. Angewandte Chemie International Edition 2002, 41, (17), 3218-
3221. 
40. Aslan, K.; Pérez-Luna, V. H., Surface Modification of Colloidal Gold by 
Chemisorption of Alkanethiols in the Presence of a Nonionic Surfactant. 
Langmuir 2002, 18, (16), 6059-6065. 
41. Lakowicz, J., Energy Transfer. In Principles of Fluorescence Spectroscopy, 
Springer US: 2006; pp 443-475. 
 
 
117 
 
42. Singh, V.; Nair, S. P. N.; Aradhyam, G. K., Chemistry of conjugation to gold 
nanoparticles affects G-protein activity differently. Journal of Nanobiotechnology 
2013, 11, (1), 7. 
43. Wangoo, N.; Suri, C. R.; Shekhawat, G., Interaction of gold nanoparticles with 
protein: A spectroscopic study to monitor protein conformational changes. 
Applied Physics Letters 2008, 92, 133104-1. 
 
 
 
 
  
 
 
118 
 
 
 
 
 
 
 
 
CHAPTER 6 
SUMMARY AND RECOMMENDATIONS   
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6.1 Summary and Conclusion 
The overall objective of this thesis is to develop advanced nanoparticles (NPs) with well-
tailored surface modification and/or bioconjugation for the applications in cell tracking, 
and target molecule detection. Since 1990’s, development of well-defined NPs in terms 
of particles size and shape has evolved into the formation of more complex nanosystems 
by combining more than two components together at nanoscale, including layer-by-layer 
NPs, core-shell NPs, and organic-inorganic hybrid nanostructures. In this thesis, hybrid 
NPs with special and enhanced luminescent and magnetic properties have been 
developed through cost-effective chemical processes. To further apply these hybrid NPs 
with enhanced chemical and physical properties in bio-imaging and bio-sensors, I applied 
different strategies to engineer the hybrid NPs: (1) modify the surface of the hybrid NPs 
to enhance their biocompatibility for achieving in vitro bio-imaging; (2) bioconjugate the 
hybrid NPs with enzyme(s) to develop BRET nanostructured sensors. The results of my 
study are briefly summarized below. 
Develop biocompatible luminescent hybrid NPs for cell-tracking. In Chapter 3, the 
biocompatible luminescence quantum dots (QDs) have been incorporated into gelatin 
nanoparticles (NPs) through two different methods, i.e. QDs-GNP1 by encapsulating 
QDs with gelatin polymer and core-shell QDs-GNP2 by layer-by-layer (LBL) coating 
approach, respectively. Both gelatin/QDs systems exhibit bright luminescence and good 
biocompatibility. No study has been found in using LBL techniques to prepare QDs 
loaded gelatin NPs. The main points are summarized below. 
1. By comparing to two synthesis processes, LBL technique indicate its advantage to enhance 
the photostability of QDs over the directly encapsulation method. 
2. Using LBL technique, QDs-GNPs show the typical core-shell structure. The shell made of 
assembled QDs is modified by a negatively charged layer to enhance the interaction with 
NIH/3T3 mouse fibroblast cells 3T3. 
3. Polyelectrolytes (PE) mediated LBL coating can improve  the quantum yields  of QDs by 
nearly two folds, and the lifetime of luminescence is found three-fold longer than that of QDs 
without PE modification.  
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4. We demonstrated that the luminescence of QDs in multiple-layer QDs/gelatin NPs is of 
unique proton resistant, which indicates it could be a suitable imaging agents in certain 
environment such as cancer cells. 
Development of bioconjugated magnetic fluorescent nanomaterials for bacterial capture, 
detection and antibacterial applications – Chapter 4 describes preparation of antibiotic 
gentamicin (Gm) conjugated fluorescent magnetic nanoparticles (FMNPs) for rapid 
capture, detection and decontamination of bacteria. The NPs consist of a fluorescent 
silica shell and an iron oxide magnetic core. Initially we prepared the core-shell FMNP1 
through a one-pot reaction. The NPs were then conjugated with antibiotic gentamicin. We 
then demonstrated the gentamicin conjugated fluorescent magnetic nanoparticles (Gm-
FMNP1) were able to capture, detect and deactivate bacteria Escherichia coli. To 
improve the stability and capture efficiency, we further developed a two-step thermal 
decomposition method to produce the fluorescent magnetic core-shell nanoparticles (i.e. 
FMNP2). We extensively demonstrated the gentamicin conjugated FMNP2 (Gm-
FMNP2) were able to capture both Gram-negative bacteria E. coli andGram-positive 
bacteria Staphylococcus aureus in 1 minute.  
1. FMNPs consist of Fe3O4 core and silica shell was produced. The FMNPs exhibit 
superparamagnetic property. 
2. Gentamicin conjugated FMNPs are able to capture both E. coli and S. aureus in as fast as 1 
minute. 
3. By utilizing the fluorescent property of Gm-FMNPs, we are able to detect bacterial cells at a 
concentration as low as of 1 x 104 CFU/mL. 
4. We demonstrated 20% higher of the antibacterial efficiency of Gm-FMNPs than that of free 
gentamicin. 
Luciferase conjugated NPs for biosensing applications – Chapter 5 describes the 
development of bioluminescence resonance energy transfer (BRET) based nanosensors 
for biosensing application. A nanosensor containing a recombinant protein (pRluc) that 
consists of Renillar luciferase and a short thrombin substrate peptide at its N-terminal 
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was conjugated to gold nanoparticles (Au NPs) for detecting protease thrombin in both 
buffer and human urine sample spiked buffer. 
1. Quench of bioluminescence was found while conjugating pRluc to Au NPs. 
2. Increasing of thrombin concentration results in increasing of bioluminescence 
intensity due to release of the pRluc from Au NPs. 
3. Thrombin concentrations are measured in both buffer and human urine sample spiked 
buffer over 300 ng/mL to 300 µg/mL with proportional relationship to the recovery of 
bioluminescence. 
4. The limit of detection is achieved to be 3 ng/mL. The detection of thrombin could be 
achieved in 15 min. 
6.2 Contributions of the Research to the Current State of 
Knowledge. 
Historical perspective – Prerequisite for the use of inorganic colloidal nanoparticle in 
biomedicine is the proper surface functionalization of such NPs, which determine their 
target applications. Critical considerations for the design of such proper surface can be 
summarized below:1-3  
1. The surface can stabilized the NPs in solution, particularly in water as almost all 
biochemical processes occur in water. In some instances, hydrophobic surface is 
required to control the growth of embryonic particles and determine the size and/or 
shape of NPs. However, a ligand exchange process is necessary to bring particles 
water solubility. 
2. The surface must offer a reduction of toxicity of NPs in some instances, for example 
for in vivo applications. A comprehensive consideration of the toxicity effect includes 
in vitro and in vivo cytotoxicity, cell adhesion, circulation, etc. 
3. Capping layers can offer additional functional groups at the surface for further 
derivatization, such as conjugation with biomolecules. 
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4. A proper surface may alter the physical properties (electronic, optical, spectroscopic 
and magnetic) or chemical properties of NPs, which provides the potentials to build 
multifunctional nanotools.  
5. The surface layers can improve the mechanical and chemical performance of the NPs, 
for example protecting core against oxidation. 
6. Bioconjugated surface can ultimately determine the targeted applications of such 
NPs, as well as their efficiency and specificity.  
Advances in surface chemistry research offer a great of opportunities in manufacturing 
NPs for the use in the field of biomedicine. The overall objective of current research 
projects was the design and development of NPs with proper surface for biomedical 
applications. NPs were designed to meet as many of the above criteria as possible in 
order to promote their target applications. 
Development of biocompatible luminescent nanocomposites for bioimaging applications 
– Luminescent quantum dots (QDs) offer unique optical properties and promise 
significant advantages as a new class of imaging and analytical probes in biomedical 
field. However, since a large portion of the QDs is obtained in organic solvents, a phase 
transfer procedure is usually required before using them in biomedical applications [9]. 
Another key challenge in bio-imaging application of QDs is the inherent biological 
toxicity of some common used QDs (e.g. CdSe QDs).4, 5 A biocompatible layer is thus 
required. Although small molecules (e.g. alkanethiol acids) have been used as a simple 
and effective ligand to render hydrophobic QDs water solubility,6-11 colloidal instability 
and quenching of luminescent have been reported in such QDs due to easy oxidation of 
core materials and acid etching in certain physiological conditions.12 Encapsulation of 
biocompatible polymer layer can offer great opportunities to overcome such drawbacks, 
as they can protect the core materials from oxidation, avoid the direct interaction of 
between core and living cells, and render new chemical functionalities for further grafting 
of biomolecules.   
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The biocompatible polymer used in my study is gelatin, a nature biocompatible 
biopolymer derived from collagen. Initially, we have successfully coated QDs with 
gelatin polymer by direct encapsulation (QDs-GNP1). The nano-system was found with 
good biocompatibility and bright luminescent. To improve photostability of QDs 
encapsulated NPs, we further applied the layer-by-layer (LBL) assembly technique to 
develop a new type of gelatin/QDs core/shell nanocomposites (QDs-GNP2). To our best 
knowledge, this is the first time using LBL technique to develop a gelatin-QDs nano-
system.  
One of the significant features of our QDs-GNP2 is the stable luminescence with unique 
proton resistant property. Multiplayer coating of polyelectrolytes (PE) was found to 
enhance the QDs quantum yield and lifetime in our study. It could be attributed to that 
the PE matrix may minimize the nonradiative recombination on the surface of QDs and 
increase confinement of charge carrier.13, 14 In addition, we show the QDs-GNP2 with 
good dispersibility and extremely stable luminescence in a wide range of pH value (pH 
1.0 to 9.0). It should be noted that acid etching can cause photo bleaching of CdSe QDs,8, 
15 which limit the use of QDs in some important physiological environments, such as 
endosomes and lysosomes inside cells and tumor cells, where the pH are in moderate 
acidic range.16, 17 Therefore the pH independent photostability of our QDs-GNP2 nano-
system may offer extra advantages for use in such conditions as imaging agents.  
Furthermore, gelatin nanoparticles (GNPs) have been demonstrated as an excellent 
carrier in drug and gene delivery,18-20 it is thus possible that our system that combining 
QDs and gelatin materials can be an all-in-one tool for simultaneously using in drug 
delivery and bio-imaging applications. In addition, the negative charge of PE coating in 
our QDs-GNP2 nano-system can potentially promote the adhesion of nanocomposites to 
cells surface, which may lead to longer circulation time in vivo and hence enhance the 
efficiency for delivery of drug.21 
Multifunctional NPs for ubiquitous capture of bacteria. MNPs have been employed for 
rapid capture and detection of pathogens. The effectively and selectively targeting 
requires stable and mono-dispersive NPs, as well as proper functionality.  
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Silica coating offers great advantages, including enhanced water solubility, low non-
specific interaction and additional functionality.22 In our study, we have tried two 
approaches in preparation of fluorescent silica coated magnetic nanoparticles (FMNPs). 
One-pot synthesis approach directly renders the NPs with hydrophilic property. However, 
particles are easily to form aggregations and particle size distribution is found relative 
boarder. The two-step approach undergoes a high temperature synthesis process, which 
provides a magnetic core with good crystalline structure. The stability of the core-shell 
NPs is more stable. The small hydro-diameter of the NPs prepared by two-step method is 
potential to improve the capture efficiency. 
Surface functionality of NPs ultimately determines the interaction of NPs with biological 
species. Antibody-modified particles have found success in cell/biomolecules labelling 
and targeting. However, antibodies are only specific to certain species of pathogen.23-25 In 
our study, we conjugated a small antibiotic molecule gentamicin to FMNPs. The protein 
nature of antibodies makes them be denatured under certain conditions, such as high 
temperature, high salt concentration, extreme solution pH, solvent, etc.26 The strong 
interaction of gentamicin to cell membrane from gram-negative bacteria and some 
sensitive gram-positive bacteria enables ubiquitous capture of bacteria by our gentamicin 
FMNPs. In addition, as gentamicin is one of the few heat-stable antibiotics that remain 
active even after autoclaving, our Gm-FMNPs are potentially reusable.  Furthermore, the 
intrinsic antibacterial activity of gentamicin makes our Gm-FMNPs as an excellent 
disinfection agent. Due to the large ratio of surface to volume property of NPs, higher 
antibacterial efficiency is expected, which is in agreement with our results.  
Luciferase conjugated NPs for biosensing applications. NPs are required to conjugate 
with biomolecules (e.g. proteins) of interest for further biomedical applications. Proteins 
can be conjugated to the surface of NPs by adsorption, covalent conjugation and binding 
through bio-affinity interaction.27 However, successful conjugation of protein to NPs 
should be evaluated by several factors, such as protein activity, protein amount, 
orientation, and the interaction between nanoparticle and proteins. One of the most 
common used approaches is covalent conjugation mediated by carbodiimide chemistry. 
In our study, we have used EDC as conjugation reagent. However, we demonstrated that 
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a systematic optimization is required for EDC mediated conjugation for better assay 
performance, including the molar ratio of proteins, NPs and EDC, in agreement with 
others’ report.28 
6.3 Limitations of the Research and Suggestions for Future 
Studies 
Development of biocompatible luminescent nanocomposites for bioimaging applications 
Despite of the versatility of LBL coating technique for enhancing the MUA-QDs 
luminescent property, the QDs used in our study exhibited low quantum yield and 
relative short lifetime comparing to the commercial products. The colloid stability of 
MUA coated QDs is relative poor, which could be attributed the desorption of MUA 
from the surface of QDs.12, 29 It is suggested that PEG derived polymer or copolymer may 
be used to improve the stability.30 In addition, coating of CdSe QDs with ZnS shell was 
also reported to increase the quantum yield.6 Thus, much effort is required to make QDs 
with good stability and bright luminescence. 
Targeting imaging requires specific interaction of luminescent NPs with certain cells. In 
our study, the adhesion of nanocomposites to cell membrane is based on electrostatic 
interaction and it is non-specific. It is expected that in the future work, conjugation of 
biomolecules (e.g. antibody) to nanocomposites can promote the target imaging. 
Additionally, as gelatin could be an excellent carrier for drug and gene deliver, it is 
promising to load drugs in the nanocomposites and realize simultaneous use in imaging 
and drug delivery.  
Development of bioconjugated magnetic luminescent nanomaterials for bacterial 
capture, detection and antibacterial applications. Initial objective of this study is to 
provide an all-in-one nanotool for simultaneous capture, detection and decontamination 
of bacteria. However, the detection of bacteria is our study is based on the observation of 
capture bacterial cells from fluorescent microscopy. Therefore, it is difficult to get 
quantitative results. In the future work, proper readout strategies may be required. Some 
of the common used techniques are fluorescent labelling of bacterial cell,31, 32 MALDI-
MS,33 etc. In addition, the detection sensitivity can be improved through optimizing the 
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conjugation conditions (For example, use of EDC mediated conjugation rather than 
glutaraldehyde cross-linking to improve conjugation efficiency). 
Another critical step is to test the versatility of our Gm-FMNPs in real world 
applications, such as the use in clinical diagnostic and wastewater treatment. Many 
challenges may occur, including matrix interference, antibiotic resistant bacterial strains, 
bacterial spores, etc. It seems that a combination of other technologies such as filtration 
in wastewater treatment may be required. Furthermore, magnetically capture of the 
pathogen from large sample volumes into much smaller ones allows their incorporation 
onto a microfluidic device platform for development of portable analytical tools.  
Luciferase conjugated NPs for biosensing applications. In chapter 5, we conjugated a 
recombinant luciferase to Au NPs through EDC mediated reaction. The assay sensitivity 
is largely dependent on the efficiency of luciferase released from Au NPs by thrombin 
cleavage. However, some of the luciferase molecules may remain conjugated on the NPs, 
if the position of the amino groups involved in the conjugation located at the C-terminal 
of the substrate peptide. Therefore, a proper conjugation orientation is important for 
increasing the assay sensitivity. As discussed in Chapter 2, it is promising to use 
expressed protein ligation strategy to produce site-specific conjugation of protein to NPs. 
One example is to use intein mediated conjugation approach to enhance such assay 
sensitivity.34 
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Appendix 1. Quantification of QD coated onto GNs 
The amount of QDs in the core-shell QDs-GNs with LBL coating was determined by 
measuring the emission intensity of QDs as a function of the concentration in triplicate at 
the 470 nm of excitation. The standard curve of the emission intensity of QDs as a 
function of the concentration was obtained as follows. 
 
 
Figure A1. Standard curve of the emission intensity of the QDs as a function of their 
concentration. 
  
 
 
131 
 
Appendix 2. pH value effects on fluorescence decay of QDs 
and core-shell QDs-GNP2  
Time-resolved fluorescence measurements were measured by the TM-30 Laser Strobe 
timeresolved fluorometer (Photon Technology International. PTI, London, Ontario, 
Canada). The average lifetime of QDs-GNP2 (a-d) and MUA-QDs (e-h) in pH at 1, 4, 7, 
and 9 are shown as follows, in which the experimental data are shown as dots, and 
numerical fits as lines. 
Figure A2 Fluorescence decay of QDs-GNP2 (a-d) and CdSe QDs (e-h) when the pH 
value of aqueous media is 1, 4, 7, and 9, respectively; the experimental data are shown as 
dots, and numerical fits as lines. 
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Appendix 3. XANES spectra of FMNPs 
 
 
Figure A3 Fe K-edge XANES spectra of FMNPs (black line) and model compound, 
Fe3O4 (red line) 
  
 
 
137 
 
Appendix 4. Determine the concentration of gentamicin on 
Gm-FMNP1. 
 
 
 
Figure A4. UV-vis spectra of the o-phthalalehyde derived gentamicin products from 
standard gentamicin solutions. 
Table A1. Absorption values at 292 nm of o-phthalalehyde -derived Gm-FMNPs 
UV Absorption  Sample of Gm-FMNP1 (fresh 
sample, 0.5 mg/mL) 
Sample of Gm-FMNP1 (sored for 
two months, 0.5 mg/mL) 
Absorbance 2.44 2.15 
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Appendix 5. Plasmid map of recombinant protein pRluc 
 
Figure A5. Map of plasmid containing recombinat protein pRluc (Obtained by 
PlasMapper web server, http://wishart.biology.ualberta.ca/PlasMapper/) 
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Appendix 6. TEM image of Au NPs and SDS-PAGE of pRluc 
 
Figure A6 (a) TEM image of Au NPs and (b) SDS-PAGE of pRluc 
 
  
(b) (a) 
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